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Chemical Investigation of the Antarctic Marine Invertebrates 
Synoicum adareanum and Artemisina plumosa 
 
Jaime Heimbegner Noguez 
 
ABSTRACT 
 
 Of the small percentage of organisms chemically investigated over the years as 
potential sources of natural products, much less is known about those from the marine 
realm. Despite the lack of attention they have received in comparison to terrestrial 
organisms, marine life have recently been found to represent a valuable source for 
novel bioactive compounds. Cold water marine habitats are home to a plethora of 
organisms that have the ability to produce secondary metabolites that exhibit a great 
deal of diversity in both their chemical structures and biological activities. The 
chemical investigation of these unique and relatively unstudied ecosystems is 
necessary to gain insight into the dynamics between predators and prey, while also 
making a significant impact in the field of drug discovery. Our laboratory has focused 
on the chemical investigation of invertebrates from the waters of Antarctica in search 
of bioactive secondary metabolites that can be used for the treatment of human 
pathogens.  This dissertation reports a small portion of the progress made in our 
laboratory towards the exploration of Antarctic marine invertebrates. The chemical 
investigation of the circumpolar colonial tunicate Synoicum adareanum and the 
orange, encrusting sponge Artemisina plumosa will be discussed in detail in the 
following chapters. 
  
 
CHAPTER ONE: 
Natural Products as Drug Leads 
 
1.1 Natural Products as Therapeutic Agents 
Although a significant amount of research has been done in an effort to better 
understand nature only a small fraction of the world’s diversity has been explored to date 
in terms of bioactivity and drug potential. Of the 250,000 species of higher plants that 
exist approximately 5-10% of them have been chemically investigated,1 along with an 
even lower percentage of the 200,000+ invertebrate and algal species contained in the 
world’s oceans.2 Investigation of these organisms has led to the isolation and structure 
elucidation of bioactive secondary metabolites that can be used for the treatment of a 
number of human ailments.3 The use of natural products, typically plants, as a source of 
therapeutic agents has continued for thousands of years and their uses have evolved from 
traditional medicines into modern drugs.  
 One of the best examples of this is the evolution of Aspirin into the most widely 
used medication in the world. The therapeutic use of willow bark dates back more than a 
thousand years to as early as 400 BC and was chewed on or steeped into a tea in order to 
reduce fever, inflammation, and pain. In the early 1800’s the active ingredient, salicylic 
acid (1), derived from the metabolism of salicin (2), was isolated and by the mid 1800’s 
derivatization of the compound had begun.4 By the late 1800’s the synthesis of a more 
1 
 
stable and less-irritating form of the natural product, acetyl salicylic acid (3), had been 
achieved by acetylation and was marketed as Aspirin® by Bayer in 1899.3 Aspirin® is 
still being used today to as an analgesic, anti-pyretic, and anti-inflammatory agent but 
since its discovery it has also been found to be an effective preventative treatment against 
heart attacks and strokes.3 
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1.2  The Impact of Natural Products on the Pharmaceutical Industry 
In 2000, approximately 60% of the drugs in clinical trials against cancer were of 
natural origins.1 And in 2001, eight of the thirty top selling drugs were natural products 
or their derivatives and they totaled $16 billion in sales.1 Furthermore, a survey made by 
the National Cancer Institute in 2003 revealed that 61% of the 877 small-molecule 
chemical entities introduced as drugs worldwide during 1981-2002 could be traced to or 
were inspired by natural products.5 The 61% was further broken down to include: natural 
products (6%) and their derivatives (27%), synthetic compounds with pharmacophores 
derived from natural products (5%), and synthetic compounds designed to mimic a 
natural product (23%).4  These statistics make it clear that natural products have 
undeniably played an important role in our pursuit of the discovery of new drugs. 
The inherent characteristics of natural products as being relatively small (<2000 
Da) and offering incomparable structural diversity ensures that they will continue to be 
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considered one of the major sources of new drugs in the future. For years, natural 
products have been inspiring chemists with their rich structural diversity and complexity 
proving that even the most creative scientist cannot outdo nature. The endiyne antibiotic 
calicheamicin6 (4) derived from the bacteria Micromonospora echinospora and the ion 
channel blocker zetekitoxin AB7 (5) isolated from the Panamanian golden frog Atelopus 
zeteki are prime examples of some of the unimaginably complex compounds designed by 
nature. 
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In addition to their uses as drugs in their unmodified state, natural products will 
also contribute to the search for new drugs by acting as chemical scaffolds that can be 
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used to synthesize more complex molecules and by indicating new modes of 
pharmacological action that allow complete synthesis of novel analogs.1 Pharmaceutical 
companies can also use the structural scaffolds of published natural products of 
pharmacological interest as templates for the identification of similar molecules in their 
existing chemical libraries, or as starting points for chemical modification.8 A few natural 
products that have been used as chemical scaffolds for current drugs are compactin9 (6), 
rapamycin10 (7), and taxol11 (8). Compactin, also known as mevastatin, is a 
hypolipidemic agent originally isolated from the mold Penicillium citrinum.8  Since the 
compound’s discovery in the 1970’s a number of cholesterol-lowering derivatives have 
been synthesized including atorvastatin (9), marketed by Pfizer under the trade name 
Lipitor®, and its competitor cerivastatin (10) marketed under the trade names Baycol® 
and Lipobay® by Bayer. 
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The natural product rapamycin is an immunosuppressant and antifungal drug 
produced by the bacterium Streptomyces hygroscopicus that was originally isolated from 
a soil sample from Easter Island.9 Rapamycin is also known as sirolimus and is marketed 
under the trade name Rapamune® by Wyeth as an immunosuppressant drug used to 
prevent rejection in organ transplantation. The synthetic derivatives everolimus 
(Certican®, Afinitor®, 11) and temsirolimus (Torisel®, 12) are being marketed as 
immunosuppressant agents as well by the pharmaceutical companies Novartis and 
Wyeth, respectively. Another sirolimus derivative recently renamed ridaforolimus (13), 
formerly known as deforolimus, is being co-developed by Merck and ARIAD and is in 
phase III clinical trials for metastatic soft-tissue and bone carcinomas responsive to 
chemotherapy.  
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 13 
Docetaxel (14) is a semi-synthetic analog of taxol (8) which was isolated from the 
rare Pacific yew tree Taxus brevifolia.10 Taxol® was commercially developed by Bristol-
Meyers Squibb as an anti-mitotic used in cancer chemotherapy, followed by the 
introduction of its synthetic analog docetaxel by Sanofi-Aventis under the trademark 
Taxotere® for the same treatment. The abovementioned compounds are prime examples 
of the pivotal role natural products play in the discovery and design of modern drugs. 
These drugs merely highlight some of the natural product scaffolds that continue to yield 
efficacious treatments over the years and improve the quality of life of billions of people. 
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 1.3  Drugs from the Sea 
Of the small percentage of organisms chemically investigated over the years, 
much less is known about marine organisms than other sources of natural products. 
Despite the lack of attention that they have been given in comparison to terrestrial 
organisms, marine organisms have been found to represent a valuable source for novel 
bioactive compounds.1 There are well over 17,000 published structures of marine natural 
products and hundreds of new compounds are still being discovered every year.12  
These bioactive metabolites are often produced by soft-bodied, sessile, or slow-
moving marine invertebrates that usually lack morphological defense structures such as 
spicules, spines, or a protective shell.7,13  In order for these vulnerable organisms to 
protect themselves they have evolved the ability to synthesize these toxic or distasteful 
compounds, to sequester them from their diet, or to obtain protection through symbiotic 
marine microorganisms.7,13 Ecological research has shown that these bioactive 
compounds function as chemical weapons that have evolved into highly potent inhibitors 
of physiological processes in the prey, predators, or competitors of the marine organisms 
that use them for defense.7,13  The wealth and variety of bioactive metabolites that are 
isolated from these marine organisms reflects the ecological importance of these 
constituents for the invertebrates that elaborate them.14 
The aforementioned chemical substances have been of interest in biomedical 
studies since many of them have been shown to be effective in the treatment of human 
diseases.    A few examples are the tunicate Ecteinascidia turbinata which yields the anti-
cancer agent ecteinascidin 743 (ET-743) 15, 16   (15) and the cone snail Conus magus 
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which yields the analgesic ziconotide17 (16). ET-743 exhibits potent activity against many 
soft tissue carcinomas and is being marketed by PharmaMar under the trade name 
Yondelis®.18 The marine-derived drug is the first treatment for myxoid liposarcoma to be 
released on the market in 30 years. Yondelis® is currently being studied for the treatment 
of prostate cancer, breast cancer, and childhood sarcomas.  Ziconotide is a non-opioid 
drug derived from the toxin of the piscivorous marine snail Conus magus and is currently 
being marketed by Elan as an isotonic solution under the brand name Prialt®.17, 19 Prialt® 
is prescribed for the amelioration of severe chronic pain in patients that are resistant to 
common analgesics.  
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With a number of well established marine natural products on the drug market and 
an even greater number of bioactive marine metabolites in various stages of clinical trials, 
the viability of the marine realm as a source of new drugs is undeniable. Aplidine20  (17), 
bryostatin 121 (18), dolastatin 1022 (19), and kahalalide F 23 (20) are all marine-derived 
drugs produced by a variety of organisms and are currently in the second phase of clinical 
trials. The colonial, Mediterranean tunicate Aplidium albicans produces the cyclic 
depsipeptide aplidine (17), also known as dehydrodidemnin B.20 The compound was 
recognized as a multi-factorial apoptosis inhibitor and was granted orphan drug status in 
2004 by the United States Food and Drug Administration for the treatment of multiple 
myeloma and acute lymphoblastic leukemia.18  
10 
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Bryostatin 1 (18) is a complex polyketide elaborated by the bryozoan Bulgula 
neritina found in the Gulf of California.21 This secondary metabolite was granted orphan 
status in 2001 for the treatment of esophageal cancer. Bryostatin 1 has been found to be a 
potent activator of protein kinase C (PKC) and shows promise in human clinical trials for 
its potentially useful synergistic action with other chemotherapeutic agents.24 
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The anti-tumor agent dolastatin 10 (19) was originally isolated from the sea hare 
Dolabella auricularia and later found in a marine cynobacterium of the species Symploca 
11 
 
as well.19,25  Preclinical trials on dolastatin 10 revealed that it was a cytotoxic peptide that 
exhibited potent microtubule-inhibiting and apoptotic effects against small lung cell 
cancer lines and the DU-145 human prostate cancer cell line both in vivo and in vitro.26  It 
is currently being studied in a Phase II clinical trial with patients diagnosed with 
hormone-refractory metastatic prostate adenocarcinoma.26 
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 The cyclic depsipeptide kahalalide F is produced by the green algae Bryopsis 
pennata but can be found in larger quantities in the Hawaiian sea mollusc Elysia 
rufescens which feeds on the algae.23 Kahalalide F is one member of a family of 
dehydroaminobutyric containing cyclic peptides isolated from Elysia rufescens and 
shows promise as a treatment for prostate cancer.18 The mechanism of action of this 
marine metabolite is mostly unknown and it has been classified as a National Cancer 
Institute-COMPARE negative compound, indicating the cytotoxicity it exhibits is likely 
related to a unique mode of action.18 
 
12 
 
H2N
NH
O
N
H
O
NH
HN
OO
O
HN O
NH
O
H
N
O
O
NH
O
N
ONHO
HN
O
HO
NH
O
NH
O
 
  20 
 
1.4 Cold Water Chemistry 
It is a surprising statistic that fewer than 3% of the marine natural products 
reported originate from organisms collected in polar habitats. This low percentage can be 
attributed to reasons as diverse as accessibility, the unpleasant climate, and arguments of 
low biodiversity. As a result, the majority of the marine organisms that have been 
chemically investigated over the years have been collected from tropical and temperate 
waters. The obvious outcome is that a greater number of natural products are being 
reported from organisms living in warmer habitats, overshadowing the equal potential of 
organisms living in cold climates to produce such compounds. 
The argument of low biodiversity with implications of low chemical diversity 
amongst cold-water marine organism is premature in both aspects. In fact, recent studies 
of cold-water habitats such as the sea floor of the Southern Ocean suggest that predation 
13 
 
and competition drives chemical diversity in the same manner observed for temperate 
climates.27,28  Psychrophiles thriving in these extreme climates have proven to be a source 
of chemically diverse natural products that exhibit equally diverse biological activities 
against human diseases.29 
 The bright red sponge Kirkpatrickia variolosa is an inhabitant of the Antarctic 
benthos and produces a series of pigments known as the variolins (21-24).30,31 These 
metabolites have a very unusual pyridopyrrolopyrimidine ring system that has no 
precedence in either terrestrial or marine natural products. The variolins exhibited potent 
cytotoxicity towards the P388 cell line and further studies revealed their mechanism of 
action as inhibitors of cyclin-dependent kinase (CDK).32 
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 Mixirins A, B, and C (25-27) are iturin class acylpeptides produced by the 
bacterium Bacillus sp. isolated from sea mud near the North Pole.33 All of the 
mixirins were found to be potent inhibitors of  HCT-116 human colon tumor cells.33 
14 
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 25 R = C12H25 
26 R = C9H19 
27 R = (CH2)7CH(CH3)(C2H5)  
 
 An undescribed Gram-positive bacterium originally isolated from a slurry of 
sterile seawater and sediment from a 980 m sediment core from the North Pacific was 
found to produce a family of unusual antiviral and cytotoxic macrocyclic lactones: 
macrolactins A-F (28-33), macrolactinic acid (34), and isomacrolactinic (35) acid.34  
Macrolactin A was the most bioactive compound of the series exhibiting selective 
antibacterial activity, inhibition of B16-F20 murine melanoma cancer cells in in vitro 
assays, significant inhibition of mammalian Herpes simplex viruses (types I and II), as 
well as protection of  T-lymphoblast cells against human HIV viral replication34 and 
of neuronal cells.35  
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  Desmarestia menziesii is an Antarctic brown alga that elaborates the quinone 
derivative menzoquinone (36),36 and the chromenol derivatives 37 and 38.37  
Menzoquinone was found to be the most biologically relevant of the group having 
displayed growth inhibition of the following microbes: methicillin-resistant 
Staphylococcus aureus (8 mm), methicillin-sensitive Staphylococcus aureus (6 mm), 
and vancomycin-resistant Enterococcus faecium (7 mm).37 
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 These organisms depict only a small portion of the biodiversity and chemical 
diversity waiting to be explored in cold water marine habitats. Cryophiles are an 
overlooked and untapped natural source of therapeutic agents and will hopefully gain 
more interest as viable candidates in the near future.  The potential for finding new 
drugs from the sea is infinite and deserves a second look from the pharmaceutical  
companies diverging from natural products chemistry. 
 
1.5  Research Objectives 
 Cold water marine habitats are home to a number of organisms that have the 
ability to produce secondary metabolites that exhibit a great deal of diversity not only 
in their chemical structures but in their biological activities as well. The chemical 
investigation of these unique and relatively unstudied ecosystems is necessary to gain 
insight into the dynamics between predators and prey, while also making a significant 
impact in the field of drug discovery. This dissertation reports a small portion of the 
progress made in our research laboratory towards the chemical investigation of 
marine Antarctic invertebrates as well as the ecological roles they play in the 
Antarctic benthos. 
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CHAPTER TWO: 
Chemical Investigation of the Antarctic Tunicate Synoicum adareanum 
 
2.1 Introduction 
2.1.1  The Chemistry of Cold Water Tunicates 
 Tunicates have been studied far less than other marine invertebrates in terms of 
their chemistry, especially in cold-water habitats. The minimal chemical investigation of 
ascidians endemic to these frigid climates can possibly be attributed to their hostile 
collection conditions and relative abundance in a given ecosystem. Secondary 
metabolites discovered from cold-water tunicates have been diverse in both structure and 
bioactivity and emerge primarily from colonial tunicates as opposed to solitary. A few 
examples of cold-water tunicates that have been explored chemically in recent years are 
Aplidium meridianum, Aplidium cyaneum, Aplidum glabrum, Dendrodoa grossularia, 
Clavelina lepadiformis, and Eudistoma sp. 
 The ascidian  Aplidium meridianum  collected from the South Atlantic (South 
Georgia Islands, 100 m) produces a series of brominated 3-(2-aminopyrimidine)indoles 
named the meridianins (39-45).38 The meridianins were all found to prevent cell 
proliferation and induce cell apoptosis and the majority of them also demonstrated 
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inhibition of CDKs, GSK-3, PKA and other kinases in the low micromolar range.39 This 
series of compounds has also been isolated from an Antarctic collection of the related 
tunicate Synoicum sp. found near Palmer Station.40 
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39 OH H H H 
40 OH H Br H 
41 H Br H H 
42 H H Br H 
43 OH H H Br 
44 H Br Br H 
45 H H H H 
     
 
  
 
 
 Aplicyanins A-F (46-51) are bromoindole derivatives isolated from Aplidium 
cyaneum collected by trawling at the Weddell Sea in Antarctica.41 Cytotoxic activity 
against HT-29 (colon), A-549 (lung), and MDA-MB-231(breast) tumor cell lines at 
submicromolar concentrations was exhibited by aplicyanins B, D, and F along with 
antimitotic activity.41Aplicyanins A and C, however, were inactive at all 
concentrations and E displayed only mild cytotoxicity.41 The biological data suggests 
that the presence of the acetyl moiety on the N-16 position of this group of 
compounds is vital in order to maintain any appreciable activity. 
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48 R2= OMe, R1=R3=H 
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 The diprenylquinones glabruquinone A (52), also known as desmethylubiquinone 
Q2, and its minor isomer glabruquinone B (53) were found in the Far-Eastern ascidian 
Aplidium glabrum.42  These polyprenylated quinones showed activity in the 
anchorage-independent transformation assay against mouse JB6 P+ Cl 41 cells that 
had been transformed with an epidermal growth factor as well as anticancer activity 
against HCT-116, MEL-28, and HT-460 human tumor cells with IC50 values of 12.7, 
17.5 and 50.5 μM respectively.42 
 
O
O
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52 
53  2'-cis  
 
 The first oxadiazinone alkaloid found in nature, alboinon (54), was isolated from a 
Baltic Sea collection of the solitary tunicate Dendrodoa grossularia.43 This sea squirt 
has also been found to elaborate the indole alkaloids grossularines-1(55) and -2 (56), 
dendrodoine (57), imidazalone 58 and the indole alkaloid 59.44-46 Dendrodoine 
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displayed moderated cytoxicity for L1210 leukemia cells (ID50=10 µg/mL) and no 
activity was reported for the other metabolites. 
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 Clavelina lepadiformis collected in the North Sea produces the alkaloids lepadin 
A (60), 61-64 and the pentachlorooctatriene 65.47   Lepadin A displayed a wide range 
of in vitro activity toward murine leukemia P388 (ED50, 1.2 µg/mL) and 
glioblastoma/astrocytoma (U373, 3.7 µg/mL), along with breast (MCF7, 2.3 µg/mL), 
ovarian (HEY, 2.6 µg/mL), colon (LoVo, 1.1 µg/mL) and lung (A549, 0.84 µg/mL) 
cancers.47  Alkaloids 61 and 64 also displayed significant in vitro cytotoxicity against 
human cancer cell lines.47     
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ergoline alkaloids, pibocin A and B (66, 67), were found in ascidians 
nlike 
cin B 
65 64 
 
 The 
belonging to the genus Eudistoma collected in the Northern Sea of Japan.48,49 U
pibocin A, pibocin B displays moderately cytotoxicity against mouse Ehrlich 
carcinoma cells, which may attributed to the substituted  indole nitrogen. Pibo
incorporates a unusual N,O-methylindole group that has previously been found in 
terrestrial plants exclusively. 
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 The unique chemistry and broad range of biological activities emerging from these 
urther 
2.1.2   Secondary Metabolites from the Synoicum genus 
Ascidians from the genus Synoicum have proven to be an outstanding source of 
novel m  
 shores 
g because it is 
a, 
cold-water ascidians provides ample justification for their continued study. Little is 
known about the ecosystems that these types of organisms live in due to the harsh 
environments and at times inaccessability. The intricate relationships that exist 
between  predator and prey in these under-studied cold-water habitats warrants f
investigation in order to gain more insight into the chemistry that evolves from them. 
 
arine natural products. The few tunicates that have been chemically investigated
from the Synoicum genus have yielded over a dozen new metabolites, some with 
appreciable biological activity. Samples of Synoicum castellatum collected off the
of various Australian islands were found to contain the previously discovered compounds 
quinine (68), hydroquinone (69), and chromene (70) as well as a novel 
tetrahydrocannabinol derivative (71).50 Compound 71 is rather interestin
the first derivative of tetrahydrocannabinol to be isolated from a marine source and it 
exhibits mild cytotoxicity against P388 murine leukemia, A-549 human lung carcinom
HT-29 human colon carcinoma and CV1 monkey kidney fibroblast cells.50  
O
O
 OH
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Rubrolides A-H (7 3) are a series of metaboli solated from the tunicate 
Ritterella rubra and were reported to possess antibacterial and phosphatase-inhibiting 
activity.51 Shortly thereafter rubrolides I-N (84-89) were reported from the red colonial 
tunicate Synoicum blochmanni collected from Tarifa Island, Spain.52 Of the six new 
nitrogenous metabolites, rubrolides I, K, L, and M exhibited significant cytotoxicity. 
Bioassay-guided fractionation of a collection of Synoicum n. sp. from New Zealand led to 
the isolation of rubrolide O (90), which exists as a mixture of E/Z isomers.53 Rubrolide O 
is the first anti-inflammatory rubrolide reported. 
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76  Rubrolide A, R=R’=Z=H, X=Y=Br
77  Rubrolide B, R=R’=H, X=Y=Br, Z=Cl 
78  Rubrolide C, R=R’=Z=Y=H, X=Br 
82  Rubrolide G, R=Z=H 
83  Rubrolide H, R=H, Z=C
 
 
l 
79  Rubrolide D, R=R’=Z=X=H, Y=Br 
80  Rubrolide E, R=R’=X=Y=Z=H 
 81  Rubrolide F, R=Me, R’=X=Y=Z=H
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84  Rubrolide I, X = Cl, Y = Br       
85  Rubrolide J, X = H, Y = Br        
86  Rubrolide L, X = Cl, Y = H       
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A series of weakly cytotoxic tetraphenolic, bis-spiroketals named prunolides A-C 
(91-93) were isolated from Synoicum prunum collected from North Stradbroke Island in 
Queensland, Australia.54  Rubrolide A (76), originally discovered in Ritterella rubra,51 
was isolated along with the structurally similar prunolides, which are believed to arise 
from oxidative dimerization of a rubrolide precursor.   
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Prunolide A (91) X = Br,   Y = Br 
Prunolide B (92) X = Br,   Y = H 
Prunolide C (93) X = H,    Y = H 
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Chemical investigation of the ascidian Synoicum macroglossum collected from 
the Indian Ocean near Tamilnadu, India, led to the isolation of the β–carboline guanidine 
derivative, tiruchanduramine (94).55 Tiruchanduramine showed promising inhibitory 
activity against α–glucocidase with an IC50 of 78.2 µg/mL . 
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The chemical literature for the genus Synoicum reveals that it yields a number of 
bioactive secondary metabolites with a broad range of biological activities. Further 
investigation into the chemistry produced by organisms belonging to this genus will 
undoubtedly continue to unveil new structurally intriguing compounds that will find their 
way into the drug discovery pipeline as plausible candidates. 
 
2.2 Chemical Investigation of the Antarctic Tunicate Synoicum adareanum 
Synoicum adareanum (Figure 1) is a sea squirt native to the waters of Antarctica 
and can be found in abundance near the U.S. research station (Palmer Station) on the 
Antarctic Peninsula. This colonial tunicate grows as a series of fist-sized colonies on a 
common base to form an assemblage of colonies, and can be collected from 15 to 796 
meters in depth. Chemical investigation of this marine invertebrate has revealed that its 
natural product diversity is broad, including polyketide macrolides (structurally similar to 
the antibiotic erythromycin)56, glucoshpingolipids (structurally related to fats)57, and 
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steroids (structurally related to cholesterol)58, all of which have very different structural 
features as well as functions within the organism.  
 
 
 
 
 
 
 
Figure 1. Synoicum adareanum collected at Palmer Station, Antarctica         
 (Photograph supplied by Bill J. Baker, University of South Florida) 
 
 
2.2.1 The Palmerolides 
A series of polyketide macrolides known as the palmerolides have been isolated 
from S. adareanum by previous members of our laboratory and have generated a great 
deal of interest due to their cytotoxicity and selectivity against melanoma cells along with 
their low toxicity. The palmerolides are composed of a nineteen membered ring with 
pendant hydroxyl and carbamate groups in varying positions. A single side chain is 
attached to the ring that varies in length and functionality. All compounds in the series 
have been found to contain one of three different ring systems and one of five different 
side chains.   
Palmerolides A (95), B (96), and C (97) were the first compounds isolated in the 
series, each possessing one of the three unique ring systems. Their planar structures were 
determined using a series of spectroscopic techniques including the two dimensional 
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nuclear magnetic resonance (NMR) experiments gCOSY, gHSQC, and gHMBC in 
addition to mass spectrometry. The determination of the absolute configurations however 
required a combination of both wet and dry chemical techniques, some of which is the 
subject of this dissertation. 
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2.2.2 Ring System “A” Palmerolides  
Palmerolide A (95) is the most abundant secondary metabolite produced by the 
tunicate and was the first of the series to be fully characterized including 
stereochemistry.56 The use of X-ray crystallography for the determination of the absolute 
configurations of palmerolide A’s five asymmetric centers was not possible due to the 
inability to produce a high quality crystal. Instead the commonly used wet chemical 
technique known as modified Mosher’s method was used in conjugation with the more 
advanced two dimensional NMR spectroscopic experiments ROESY and HETLOC. After 
publication it was noticed that the NMR data of the Mosher’s esters was transposed. 
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Degradative and synthetic efforts later confirmed the misinterpretation of the original 
Mosher’s data and revealed the absolute configurations as 7S, 10S, 11S, 19R and 20R.59-63 
Palmerolide A has four analogs (palmerolides D (98), E (99), F (100), and G 
(101)), all containing the same macrolide ring core but possessing different side chains. 
The absolute configurations of the stereocenters were determined, as described below, 
using the corrected structure of palmerolide A as the basis for comparison. 
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Palmerolide D (98) differs from palmerolide A (95) starting at the carboxamide 
portion of the side chain.  Just as was the case with palmerolide A, gHMBC correlations 
could be observed between a carbonyl at δ162.9 (C-1’), a methylene group at δ40.3 (C-
4’), and a methyl group at δ25.1 (C-8’) to H-2’ (δ5.81.) These correlations were 
indicative of the presence of a trisubstituted olefin in which C-2’ (δ119.7) was a 
participant.   The C-2’/C-3’ trisubstituted olefin was assigned as Z based on ROESY 
correlation between H-2’ and H3-8’ and was found to be conjugated to an amide. The 
presence of gHMBC correlations from H3-8’ (δ1.76) to C-2’, C-3’ (δ152.7), and C-4’ 
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also supported the existence of this conjugated olefin. It is at this point in the side chain 
where the differences between palmerolides A and D begin. In palmerolide A the 
carboxamide chain ends at this conjugated trisubstituted olefin whereas it is elongated in 
palmerolide D by three carbons. The extended side chain was assigned by gHMBC 
correlations from C-2’, C-3’, C-5’ (δ143.0), and C-7’ (δ22.0) to H2-4’ (δ3.34). The planar 
structure could then be completed by 
correlations from H3-7’ (δ1.61) to 
methylene C-4’, quaternary C-5’ and 
terminal methylene, C-6’ (δ111.9). The 
proposed planar structure was confirmed 
by high resolution mass spectrometric 
analysis with an [M + 1]+ peak at m/z 
625.3864 (Δmmu 1.1 for C36H53N2O7). A comparison of the contiguous carbon backbone 
of palmerolides A and D is illustrated in Figure 2. The 13C NMR spectrum shows no 
more than 2 ppm Δδ (Δδ = δ pal A - δ pal D) when compared to palmerolide A over the 
contiguous carbon backbone (Figure 2), supporting the assignment of palmerolide D as a 
homolog of palmerolide A. 
 
Figure 2.  Comparison of palmerolide D and 
palmerolide A 13C NMR chemical shifts 
by position number (Δδ = δ Pal A – δ Pal D) 
The 1H NMR spectrum of palmerolide E (99) was distinct in comparison to the 
other palmerolides because it contained a signal indicative of an aldehyde group. In 
addition, analysis of the NMR data revealed a significant reduction in the carbon and 
proton count than palmerolide A, and was later confirmed by mass spectral analysis (m/z 
512.2634 for C27H39NO7Na, calc. 512.2624).  Although there were far fewer proton and 
carbon signals, the 1H NMR spectrum of palmerolide E retained many of the macrolide 
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NMR signals originally observed in palmerolide A (95) (see, for example, Figure 3). 
Further analysis of the 2D NMR data facilitated the determination of the macrocycle as 
identical to those of palmerolides A and D, and can be appreciated from Figure 3 which 
displays a minimal difference in Δδ values of the carbons comprising the macrolide core.  
With all of the carbons in the macrolide core accounted for it became evident that the side 
chain pendant at C-19 could account for 
the missing substructures.  Assignment of 
the side chain began with correlations in 
the gCOSY and gHMBC spectra 
establishing that C-19 was adjacent to a 
C-20 methine, and could be further 
extended by correlations to the familiar C-21/C-22 olefin and its attached vinyl methyl 
group found in both 95 and 98.  The structure of palmerolide E began to stray from the 
others at this point in that the C-21/C-22 olefin was found to be conjugated to the 
aforementioned aldehyde function. Correlations in the gHMBC data between the 
aldehyde proton, H-23 (δ9.40) and both C-21 (δ154.9) and C-22 (δ138.7) terminated the 
side chain. Thorough analysis of all data obtained for the compound led to the conclusion 
that palmerolide E is not the initially expected hydrolysis product but rather 24-
norpalmerolide.  
Figure 3.  Comparison of palmerolide E and 
palmerolide A 13C NMR shifts 
     Palmerolides F (100) and G (101) were found to be isomeric with palmerolide A 
based on the HR ESIMS data (m/z:  100, 607.3359; 101, 607.3350; calc. 607.3359 for 
C33H48N2O7Na).  The carbon backbone of both compounds was established by 2D NMR 
analysis in the same manner as described for previous palmerolides. Carbons C-1 through 
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C-24, comprising the macrolide core and 
the side chain up to the amide moiety, 
were found to be identical to palmerolide 
A in both constitution and olefin 
geometry.  The 1H NMR spectrum of 
palmerolide F made it very easy to 
distinguish the carboxamide substructure as different from that in palmerolide A (95) by 
the presence of exomethylene signals of H2-4’ (δ 4.79 and 4.82). Analysis of the 13C 
NMR spectrum confirmed this observation. Working inward from the terminus of the 
side chain, the protons of the olefinic methylene C-4’ could be correlated to the vinyl 
methyl C-5’ (δ 22.2) and the vinyl methylene C-2’ (δ 44.5) using gHMBC data. 
Correlations observed from C-2’ to the carboxamide carbonyl, C-1’ (δ 167.4), was the 
last piece of data necessary to establish the carboxamide group as 3-methyl-3-butenoyl.   
Figure 4.  Comparison of palmerolide F            
13C NMR shifts to those of palmerolide A 
Palmerolide G, another isomer of palmerolide A, differed only in the geometry of 
the C-21/C-22 olefin. The configuration of the olefin was demonstrated as Z based on 
ROESY data showing a correlation between H-23 (δ 6.19) to H-20 (δ 2.65) and from H-
21 (δ 5.01) to H3-27 (δ 1.76). The difference graphs (Figures 4 and 5) for palmerolides F 
and G show little variation in the chemical shifts of the carbon backbone from that of 
palmerolide A, which is to be expected since 
they are isomers. Palmerolide G displays the 
lowest Δδ values overall being that it differs 
from palmerolide A only in the geometry of 
the C-21/C-22 olefin, affecting only the 
Figure 5.  Comparison of palmerolide G  
13C NMR shifts to those of palmerolide A
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chemical shifts of neighboring carbons as is demonstrated in Figure 5. Palmerolide F 
displays minimal differences in chemical shifts in the macrolide portion of the molecule 
with larger variations in the side chain due to the isomerization of the C-2’/C-3’ internal 
alkene to a C-3’/C-4’ terminal alkene. 
 
2.2.2.1  Stereochemical Assignment of Palmerolides D-G 
Modified Mosher’s method 64 is a wet chemical technique used for the 
configurational analysis of secondary alcohols and is considered to be an invaluable tool 
amongst natural products and synthetic chemists concerned with the absolute 
configurations of organic compounds. This technique entails the derivatization of 
secondary alcohols as the respective (R)- and (S)-α-methoxy-α-
trifluoromethylphenylacetate (MTPA) esters. Proton nuclear magnetic resonance data 
must be obtained and the 1H chemical shift differences that arise as a result of the 
diamagnetic effect of the benzene ring recorded. The Δδ values for the surrounding 
protons can then be calculated using the formula Δδ = δS – δR. Using this data a model 
can be made to reveal the absolute configuration of the chiral center by placing all 
positive Δδ values on the right side of the MTPA plane and all negative Δδ values on the 
left side as demonstrated below.64 
O
CF3
O
Ph OMe
H
(OMe) (Ph) (R)-MTPA
(S )-MTPA
HX HY HZ
HC HB HA
MTPA plane  
δ γ β 
α
γ δ β
Figure 6. Mosher’s depiction of the MTPA plane of an MTPA ester64   
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 Modified Mosher’s method was used to determine the absolute configurations of 
the two alcohols on C-7 and C-10 for all four ring system “A” palmerolides (D-G, 98-
101). The (R)- and (S)-MTPA palmerolide diesters were made by the reaction of each 
palmerolide with Hunig’s base, dimethylaminopyridine (DMAP), and an excess of the 
respective Mosher’s chloride in dry dichloromethane.  The crude reaction mixtures were 
separated using reversed phase high pressure liquid chromatography and afforded the 
pure diester, which eluted at a much lower polarity than the natural product.  Successful 
formation of the Mosher’s esters was confirmed by the presence of aromatic and methoxy 
signals in the 1H NMR spectrum. NMR data was obtained for both (R)- and (S)- diester 
products of each palmerolide and the chemical shift differences analyzed. Figures 7 and 8 
show the 1H NMR spectra obtained for the (R)- and (S)-MTPA diesters of palmerolide F 
as an example. 
0 9 8 7 6 5 4 3 2 1
Ch i l Shif ( )Figure 7. Palmerolide F (R)-MTPA diester in d6-DMSO at 500 MHz 
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10 9 8 7 6 5 4 3 2 1
Ch i l Shift ( )Figure 8. Palmerolide F (S)-MTPA diester in d6-DMSO at 500 MHz. 
 
The Δδ values for the proton chemical shifts relevant to the C-7 and C-10 
stereocenters were calculated for palmerolides D-G and are reported in Table 1 along 
with the model constructed from them.  The corrected Δδ values obtained for palmerolide 
A are also included. Application of modified Mosher’s method revealed the 
configurations to be 7S and 10S in all ring system “A” palmerolides. 
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Table 1. Stereochemical analysis (Δδ) of Palmerolides A-G (53, 56-59) 
using Mosher’s method[a] 
 
H H
H H H
H
H H
O H
R
H O
MTPA
O H
MTPA
5 6 7 8 9
10 11 12
 
Δδ 
variable
Δδ+ Δδ-
 
 Pal A Pal D Pal E Pal F Pal G 
H-5a -- -10 -10 -20 -- 
H-5b -150 -- -- -- -130 
H-6a -20 -30 -30 -40 -30 
H-11 +110 +130 +140 +90 +140 
H-12 +180 +170 +150 +130 +120 
 [a] All Δδ values multiplied by 1000 
 
The absolute configurations of the C-11, C-19, and C-20 stereocenters were 
determined based on simulation of the 1H NMR signals. Since palmerolides D-G all have 
the same ring system as palmerolide A a comparison of the coupling constants of the 
relevant protons could secure the absolute configurations. It was anticipated that ring 
analogs having the same absolute configuration as palmerolide A at a particular 
stereocenter would have the same coupling constants while diastereomers would have 
different coupling constants. This supposition was based on the knowledge that each 
proton has a unique 1H NMR signal inherent to its environment, the splitting pattern 
being indicative of the number of spin system couplings and the configuration being 
indicative of their location in space.  Table 2 illustrates a comparison of palmerolide A’s 
coupling constants to those extracted via 1H NMR simulation for palmerolides D-G. All 
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of the coupling constants for the respective stereocenters were found to be within 1 Hz of 
those of palmerolide A, strongly supporting the hypothesis that their stereochemistry 
would be the same since they are ring analogs. This enabled the stereochemistry of all 
ring system A palmerolides (A, D, E, F, and G) to be assigned as 7S, 10S, 11S, 19R, 20R. 
 
Table 2. 3JH,H (Hz) analysis of key palmerolide stereocenters 
 Pal A Pal D Pal E Pal F Pal G 
J10,11 4.8 5.0 5.0 5.1 4.8 
J11,12 10.6 10.6 10.7 10.7 10.3 
J18a,19 1.3 1.4 1.4 1.7 1.5 
J18b,19 11.2 11.0 11.0 12.0 12.0 
J19,20 10.0 10.0 9.9 9.7 10.0 
J20,21 8.0 8.0 7.0 7.3 8.0 
J20.26 6.6 6.6 6.9 7.0 6.6 
 
 
 
 
 
2.2.3 Ring System “B” Palmerolides  
The “B” ring system is unique in that it is the only one of the three distinct 
palmerolide cores that possesses a sulfate group. The presence of the sulfate group 
significantly increases the polarity of the compounds containing this macrocycle in 
comparison to the previously described palmerolides and appears to be responsible for 
their lack of stability in dimethylsulfoxide (DMSO). Palmerolides B (96) and H (102) are 
the only two palmerolides found so far that contain the “B” ring system. Despite their 
unique macrolide cores these compounds contain side chains originally observed in the 
rings system A analogs. Palmerolide B has the same side chain as palmerolide A, and 
palmerolide H shares the same extended side chain as the previously described 
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palmerolide D. Their planar structures were determined using the same techniques used 
to elucidate the ring system “A” palmerolides with the exception of the sulfate group.  
Mass spectral analysis of palmerolides B and H using ESI-MS in positive ion mode gave 
the parent ions [M+1] 567.3 m/z and 607.3 m/z respectively, suggesting the sulfate group 
eliminated during the mass spectral analysis. Running the samples using ESI-MS in 
negative ion mode gave the respective parent ions [M-1]- 663.3 m/z and 703.3 m/z, 
establishing the presence of a sulfate group by mass spectrometry. 
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The ring system “B” macrocycle was constructed starting at the C-1 (δ168.2) ester 
carbonyl which showed gHMBC correlations to the olefinic protons H-2 (δ5.70) and H-3 
(δ6.74), indicating the same α,β-unsaturated ester seen in ring system “A”. The C-4 
(δ34.0), C-5 (δ26.1) and C-6 (δ31.8) methylene groups were assigned based on gHMBC 
correlations to H-3 and their positions corroborated by gCOSY data as was done with 
palmerolide A. The H-7 (δ4.57) oxymethine showed gCOSY coupling to the H-6 (δ1.55, 
1.08) methylene protons and another oxymethine located on C-8 (δ72.1). Coupling 
between H-7 and a quaternary carbonyl (δ159.8) suggested the presence of the carbamate 
group as seen in palmerolide A on C-11, and was confirmed by mass spectral analysis. 
The C-9 (δ133.4)/C-10 (δ131.0) olefin was found to be flanked by the H-7 and H-11 
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(δ4.64) oxymethines, which were subsequently determined to be attached to carbons 
bearing hydroxyl and sulfate groups, respectively. This functional group motif is similar 
to that seen in the ring system A palmerolides but the order of oxygenation is different in 
that the two adjacent oxygenated moieties are closer to the beginning of the macrocycle 
(C-7/C-8) as opposed to the middle (C-10/C-
11). The connectivity of methylene groups 
C-12 (δ1.79, 1.53) and C-13 (δ1.96, 1.21) 
could be established by both gCOSY and 
gHMBC correlations. Another disubstituted 
olefin was place between C-14 (δ133.3) and 
C-15 (δ128.0) and was determined to be 
trans based on the coupling constants 
(J14,15=14.5 Hz) of methines H-14 (δ5.38) 
and H-15 (δ6.01). The macrocycle was 
further extended by gHMBC correlations 
from H-15 to a conjugated trisubstituted 
alkene positioned between C-16 (δ129.8) 
and C-17 (δ132.8), as well as the vinyl 
methyl C-25 (δ16.7). In addition, vinylic 
methyl H3-25 (δ1.58) could be correlated to 
C-15, C-17, and C-18 (δ45.2). Ring closure 
was established by gCOSY correlations 
from non-equivalent methylene H2-18 (δ2.15, 1.99) to oxymethine H-19 (δ4.82),  
Figure 9.  Comparison of palmerolide B     
13C NMR shifts to those of palmerolide A
Figure 10.  Comparison of palmerolide B      
13C NMR shifts to those of palmerolide H
Figure 11.  Comparison of palmerolide H     
13C NMR shifts to those of palmerolide D
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followed by gHMBC correlations to C-20 (δ2.68) of the side chain and the C-1 (δ168.2) 
ester carbonyl. Figure 9 illustrates a comparison of the carbon backbones of palmerolides 
B and A. The graph cleary depicts the differences in the macrolide cores by the large Δδ 
values for C-4 through C-12, and that they possess the same side chain by the negligible 
differences in the chemical shifts of the side chain carbons.The assignment of 
palmerolide H as having the same ring system as palmerolide B is illustrated in Figure 10 
and the same extended side chain as palmerolide D is illustrated in Figure 11. 
 
2.2.3.1 Stereochemical Assignment of Palmerolides B and H 
 Since a formal synthesis of palmerolide B has not been completed it was 
necessary to modify the approach used to determine the absolute configurations of the 
stereocenters from that used with the “ring system A” compounds. Proton NMR 
simulation could still be used to determine the threo configurations of the C-19 and C-20 
stereocenters by comparison of the J-coupling constants with those of palmerolide A 
(Table 3). The extracted J-values indicate that palmerolides B and H have the same (R, 
R)-configuration at these stereocenters as palmerolide A.   
 
Table 3. 3JH,H (Hz) analysis of key palmerolide stereocenters 
in palmerolides A, B, and H 
 
 
 Pal A Pal B Pal H
J19,20 10.0 9.7 9.7 
J20,21 8.0 7.9 7.9 
J20.26 6.6 6.6 6.6 
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The relative stereochemistry of the C-7 and C-8 stereocenters was determined via 
another popular method of J-based configuration analysis using the advanced two-
dimensional NMR experiment gHSQMBC.65 As is indicated by its title, this experiment 
is a combination of the two dimensional heteronuclear NMR experiments gHSQC 
(gradient heteronuclear single quantum coherence) and gHMBC (gradient heteronuclear 
multiple bond coherence). The experiment illustrates heteronuclear single bond 
correlations as well as heteronculear multiple bond correlations within three bond 
proximity. In addition, this experiment can also be used to extract two and three bond 
heteronuclear coupling constants which can reveal the relative position of two adjacent 
groups in space. This method was developed by Murata who demonstrated a correlation 
between the values/magnitude of three bond homonuclear (3JH,H), two bond heteronuclear 
(2JC,H), and three bond hetereonuclear (3JC,H) spin-coupling constants to the relative 
position of two adjacent oxygenated groups.66 Murata’s method works because in 
systems with conformational changes, such as macrocycles, the coupling constants are 
observed as a weighted average of those due to each conformer. Although vicinal proton-
proton couplings (3JH,H) can be extracted easily from a proton spectrum, these values 
alone are not enough for configuration analysis because they cannot distinguish between 
two gauche rotamers. The additional information that can be gained from 2,3JC,H coupling 
constants, however, may dramatically expand the utility of the coupling constants by 
providing a distinction between the two gauche rotamers. Table 4 contains the values and 
magnitudes of the coupling constants outlined by Murata for the anti and gauche 
orientations in acyclic systems.66 
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Table 4. 3JH,H and 2,3JC,H Values (Hz) for anti and gauche 
orientations in acyclic systems 
 
  3JH,H 2JC,H 3JC,H 
oxygenation Anti large
Gauche
small 
Gauchea
large 
Antib 
small
Anti 
large 
Gauche 
small 
di 7-10 0-3 -4 to -6 2-0 5-7 1-3 
 
 
 
a,b   Oxygen functions on relevant carbons are gauche and 
 anti to their  vicinal protons respectively 
 
 
 
Palmerolides B and H fall under the category of di-oxygenated systems (located 
on C-7 and C-8) and the spin coupling values extracted from the NMR data can be found 
in Table 5. The application of Murata’s method reveals that the relative stereochemistry 
of the C-7 carbamate and C-8 hydroxyl groups of both palmerolide B and H are gauche 
as illustrated in Figure 12. It should be noted that although the arrangement of the 
secondary alcohol and carbamate groups are in different positions on the rings relative to 
those of palmerolide A, the relative stereochemistry of these moieties remains the same.  
 
Table 5. 3JH,H  and  2,3JC,H values for palmerolides B and H 
Spin 
Couplings Palmerolide B Palmerolide H 
 
3JH,H     H7-H8 
 
~2.0 Hz (small) ~2.0 Hz (small) 
 
2JC,H    H7-C8 
 
~ -4.0 Hz (large) ~ -5.0 Hz (large) 
 
3JC,H     H8-C6 
 
~ 1.5 Hz (small) ~ 2.5 Hz (small) 
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Figure 12. Newman projection of palmerolide B C-7/C-8 stereocenters 
 
In order to elucidate the absolute configurations of the C-7 and C-8 stereocenters 
modified Mosher’s method was attempted. Unfortunately, due to the presence of the 
sulfate group on C-11 preparation of the Mosher’s esters was elusive. Several attempts at 
mild acid hydrolysis of the sulfate group proved unsuccessful and other methods found in 
the chemical literature seemed too abrasive for such a complex molecule with so many 
labile moieties. Palmerolide B was reacted with sodium methoxide in an attempt to 
hydrolyze the sulfate group so that Mosher’s method could subsequently be used to 
elucidate the absolute configuration of the three resulting secondary alcohols. Separation 
of the crude reaction mixture by reversed phase chromatography using a gradient from 
50% water/methanol to 100% methanol indicated the formation of a compound that was 
significantly less polar than palmerolide B according to its retention time. 1H NMR data 
was obtained on this fraction and the compound appeared to be very similar to 
palmerolide B based on a superficial comparison against previously acquired data. A 
more in depth analysis of the compound revealed that it had undergone hydrolysis of the 
C-7 carbamate group as well as elimination of the C-11 sulfate group (103). ESI mass 
spectral analysis gave a parent ion [M+1] of 524.3 m/z confirming the proposed structure, 
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and no ionization was observed when run in negative mode which ultimately confirmed 
the absence of the sulfate group. 
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Following removal of the sulfate group via base hydrolysis, the respective C-8 
MTPA Mosher’s monoesters of compound 103 were made and full NMR data sets 
acquired. Analysis of the data revealed the absolute configuration of C-8 to be in the S 
configuration (Table 6). The absolute configuration of C-7 could subsequently be 
assigned as S based on the prior application of Murata’s method.  Tables 3 and 5 above 
show comparisons of the key coupling constants for palmerolides B and H which 
suggests that their stereochemistry is the same. The successful application of Mosher’s 
method on the palmerolide B analog 103 allowed for the stereochemical assignment of 
palmerolides B and H as 7S, 8S, 19R, 20R.  
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Table 6. Stereochemical analysis (Δδ) of palmerolides B (96) 
using Mosher’s method (all Δδ values multiplied by 1000) 
 
H
H
O H
MTPA
H OH
H H
678910
Δδ + Δδ - 
 
 
 1H 
position Pal B 
H-4 +80 
H-6 +40 
H-7 +10 
H-9 -10 
H-10 -10 
H-11 -10 
 
 
 
 
 
Further studies will have to be performed in order to elucidate the configuration 
of the sulfate bearing C-11 stereocenter. Since the base catalyzed hydrolysis leads 
primarily to the C-11 dehydrated product, synthetic analysis appears to be the most 
logical avenue to pursue. There are a number of syntheses described for palmerolide A 
which could potentially be modified to enable a relatively quick synthetic route to 
palmerolide B. Comparison of the synthetic palmerolide B diastereomers to the natural 
product would allow for the relatively quick determination of the C-11 configuration. 
 
2.2.4 Ring System “C” Palmerolides 
 Palmerolides C (97) and K (104) are the only compounds found so far that contain 
the ring system “C” macrolide core.  Despite that the molecular weight of palmerolide C 
was determined to be the same as palmerolide A via mass spectrometry, and that the 1H 
NMR data of the side chain protons was identical, it was evident from the 1H NMR 
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spectrum that this compound had undergone a significant rearrangement of the structural 
features within the macrolide core (Figure 13). Although it shares the same oxygenated 
moieties as the ring system A analogs, these groups are compacted to the C-8, C-9, and 
C-10 carbons of the backbone as opposed to being separated by the familiar disubstituted 
olefin.  
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The α,β-unsaturated ester found in the other palmerolide rings systems was 
confirmed in the “C” ring system as well by gHMBC correlations from olefinic H-2 
(δ5.73) to the C-1 (δ166.9)  ester carbonyl 
and C-3 (δ149.8)  methine. Vinyl proton H-3 
(δ6.77) showed gHMBC correlations to 
methylenes C-4 (δ31.7) and C-5 (δ32.2) 
which further extended the carbon backbone. 
Aliphatic H-5 (δ1.93, 1.84) could be 
correlated to a disubstituted alkene 
positioned between C-6 (δ131.8) and C-7 (δ131.1) through both gCOSY and gHMBC 
data. A vicinal diol on C-8 (δ72.8) and C-9 (δ75.6) was identified by gCOSY correlations 
from oxymethine H-8 to vinyl H-7 (δ5.58) as well as oxymethine H-9 (δ3.56). A third 
Figure 13.  Comparison of palmerolide C       
13C NMR shifts to those of palmerolide A
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oxymethine could be placed on C-10 (δ74.2) based on gCOSY correlations from fellow 
oxymethine H-9 and aliphatic H2-11 (δ1.49, 1.30) to H-10 (δ4.56). This was confirmed 
by gHMBC signals from aliphatic H2-12 (δ1.95) to C-10. A correlation to an ester-type 
carbonyl moiety was observed for H-10 as well, which upon mass spectral analysis was 
found to be the familiar carbamate seen in the other palmerolide ring systems. A series of 
methylene groups could be placed from C-11 (δ28.7) to C-13 (δ30.1), and the macrocycle 
closed the same as the A and B ring systems with the trans C-14 (δ132.3) /C-15 (δ127.2) 
disubstituted olefin correlating to the C-16 (δ128.8) /C-17 (δ132.5) trisubstituted olefin. 
H3-25 (δ1.69) demonstrated gHMBC correlations to C-16, C-17, and C-18 (δ44.1) 
consistent with its assignment as a vinyl methyl. The 20-membered macrocycle was 
closed by gHMBC correlations from H-19(δ4.85) to C-1, C-17 and C-18. Palmerolide C 
was found to have the same side chain as palmerolides A and is illustrated in Figure 13 
by the minimal chemical shift differences from C-19 onward. Figure 14 demonstrates that 
palmerolides K shares the same ring system as palmerolide C, while Figure 15 shows that 
it contains the same truncated side chain as palmerolide E. 
 
Figure 14.  Comparison of palmerolide C       
13C NMR shifts to those of palmerolide K
Figure 15.  Comparison of palmerolide K 
13C NMR shifts to those of palmerolide E
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2.2.4.1  Stereochemical Assignment of Palmerolides C and K 
 Stereochemical assignment of palmerolides C (96) and K (104) required a 
combination of the techniques used to determine the absolute configurations of the ring 
system “A” and “B” palmerolides. Proton NMR simulation and extraction of coupling 
constants could be used to determine the configurations of C-19 and C-20 as was done 
with the other palmerolides (Table 7). Extraction of the J-values indicated that the 
relative configurations of the C-19 and C-20 sterocenters are threo. By analogy with the 
other palmerolides, the absolute stereochemistry is assumed to be 19R and 20R. 
 
Table 7. 3JH,H (Hz) analysis of key palmerolide stereocenters 
             in palmerolides A and C 
 
 
 Pal A Pal C
J19,20 10.0 9.8 
J20,21 8.0 7.6 
J20.26 6.6 6.7 
 
   
 
  
 The relative stereochemistry of the C-8/C-9 diol in palmerolide C was 
determined using gHSQMBC data and Murata’s method. Configuration analysis using 
the extracted J-coupling constants suggested that the hydroxyl groups were in the anti 
conformer (Figure 16, Table 8). The same type of analysis was conducted to determine 
the relative stereochemistry of the C-9 hydroxyl and C-10 carbamate groups. The data 
indicated that the C-9/C-10 stereocenters were in the gauche conformer (Table 8). 
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Figure 16. Newman projections of palmerolide C 
C-8/C-9 (A) and C-9/C-10 (B) stereocenters
 
 
 
 
Table 8. 3JH,H  and  2,3JC,H Values for palmerolide C 
 
 
C-8/C-9 Analysis C-9/C-10 Analysis 
Spin Couplings Palmerolide C Spin Couplings Palmerolide C
3JH,H    H8-H9 ~7.0 Hz 3JH,H     H9-H10 ~2.0 Hz 
2JC,H    H9-C8      ~ -5.5 Hz 2JC,H    H10-C9 ~ -5.0 Hz 
3JC,H     H9-C7 
           H8-C10 
~ 3.0 Hz 
~ 3.0 Hz 
3JC,H      H10-C8 
            H9-C11 
~ 7.0 Hz 
~ 2.5 Hz 
 
 
 
 
  
 Modified Mosher’s method was used initially to assign the absolute 
configurations of the C-9 and C-10 stereocenters. Synthesis of the Mosher’s diester was 
performed but assignment of the stereochemistry remained elusive since the Δδ values 
were all the same sign. This effect can occur when vicinal diols are derivatized and the 
resulting esters are unable to position themselves far enough away from each other due to 
restricted rotation around the bond. The solution to this problem was to make the 
respective R and S monoesters of the C-8 hydroxyl group in order to figure out the 
absolute configuration of C-8. The Δδ values for the surrounding proton chemical shifts 
along with the model constructed from them can be found in Table 9. Assignment of C-8 
as being in the S configuration via Mosher’s method allowed for the indirect assignment 
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of the other stereocenters as 9R and 10S based on the prior application of Murata’s 
method. A comparison of the coupling constants of palmerolides C and K (Table 10) 
proved the absolute stereochemistry of both compounds to be 8S, 9R, 10S, 19R, 20R. 
 
 
 
Table 9. Stereochemical analysis (Δδ) of palmerolides C (97) 
using Mosher’s method (all Δδ values multiplied by 1000) 
 
H
H
O H
MTPA
H OH
H OR
6
7
8 9 10
Δδ + Δδ - 
 
 
 1H 
position Pal C 
H-6 -90 
H-7 -100 
H-9 +110 
H-10 +40 
 
 
 
 
 
 
 
Table 10. 3JH,H (Hz) analysis of key palmerolide stereocenters 
in palmerolides C and K 
 
 
 Pal C Pal K
JH8,9 2.0 2.0 
JH9,10 2.0 2.0 
JH19,20 9.8 9.6 
JH20,21 7.6 8.0 
JH20.26 6.7 6.5 
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2.3 Structure Activity Relationship Studies on Palmerolide A 
2.3.1 Bioactivity of the Palmerolides 
 The discovery of  palmerolide A generated a great deal of interest due to the 
potent cytotoxicity and selectivity exhibited in the National Cancer Institute’s (NCI) sixty 
cancer cell line panel along with its low toxicity. Palmerolide A displayed impressive 
activity against the UACC-62 melanoma cell line with an IC50 of 18 nM.56 The NCI’s 
COMPARE database found that palmerolide A had a dose response profile against the 
cancer cell lines that was very similar to those exhibited by the natural products 
bafilomycin A1 (105)65 isolated from the bacteria Streptomyces griseus, and 
salicylahalamide A (106)66 isolated from the sponge Haliclona sp. These compounds act 
as potent inhibitors of mammalian vacuolar-ATPase and prompted the assay of 
palmerolide A for such activity.67,68 Palmerolide A was found to act as a potent inhibitor 
as well with an IC50 of 2 nm but lacked the neurotoxicity observed with compounds 105 
and 106. 
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All of the palmerolides were evaluated for cytotoxicity against UACC-62 
melanoma cells via an in house assay as well as for their ability to inhibit mammalian v-
ATPase (Table 11, conducted by X. S. Xie, University of Texas Medical Center, Dallas). 
The range in bioactivity exhibited by the palmerolides is indicative of a delicate balance 
between substructures within the side chain and the macrolide core. This order of 
reactivity of the macrolide cores can best be observed in the bioactivity data collected for 
palmerolides A, B, and C, which all possess the same side chain but have differing ring 
systems. The data suggest that the “A” ring system is the most bioactive overall against 
v-ATPase and UACC-62 melanoma cells with palmerolide A exhibiting IC50 values of 2 
nm and 0.024 µM, respectively. Palmerolide B was found to be the second most active 
against v-ATPase with an IC50 of 0.023 µM but the least active of the three against 
UACC-62 cells at 0.25 µM. Despite that palmerolide C is approximately 10-fold less 
potent against v-ATPase than palmerolide B with an IC50 of 0.150 µM, it is more active 
against UACC-62 cells by 2-fold at 0.11 µM.  These findings indicate that the 
arrangement of the functional groups in the macrolide core do in fact influence the 
bioactivity of the compound, but also implies that different substructures within the ring 
may be responsible for the activities exhibited against UACC-62 and v-ATPase. 
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Table 11.  Bioactivity data for palmerolides (IC50 values in µM) 
    
Compound 
vATPase 
(µM) 
Melanoma 
(µM) v-ATP:cytotoxicity ratio mammalian UACC-62
PalmerolideA 0.002 0.024 0.083 
PalmerolideB 0.023 0.250 0.092 
Palmerolide C 0.150 0.110 1.364 
Palmerolide D 0.025 0.002 12.500 
Palmerolide E 10.000 5.000 2.000 
Palmerolide F 0.063 0.758 0.083 
Palmerolide G 0.007 1.207 0.006 
Palmerolide H 0.021 0.019 1.105 
Palmerolide K 10.000 >10.000 > 1.000 
 
 
 
 
 
 
 
The “A” ring system also proved to be the most potent when comparing 
palmerolides E and K. Palmerolides E and K both possess the truncated side chain but 
differ in that palmerolide E possess the “A” ring system and palmerolide K contains the 
“C” ring system. Although they both lack activity against v-ATPase with equivalent IC50 
values of 10 µM, palmerolide E is more active than palmerolide K exhibiting inhibitory 
activity against UACC-62 cells at 5 µM as opposed to >10 µM.  
This is also the case for palmerolides D and H both of which contain the extended 
side chain. Palmerolide D which possesses the “A” ring system proves to be more potent 
in terms of cytotoxicity than palmerolide H which bears the “B” ring system, 
demonstrating IC50 values of 0.002 µM and 0.019 µM, respectively. When compared by 
their ability to inhibit v-ATPase, however, they were equipotent for the most part with 
respective IC50 values of 0.025 µM and 0.021 µM. This data suggest that although the 
arrangement of the macrolide core influences overall bioactivity, it may have a greater 
impact on cytotoxicity than v-ATPase activity. Perhaps more importantly this set of data 
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suggests that substructures within the side chain exert more influence on overall 
bioactivity than those in the macrolide core. 
By performing a bioactivity comparison of all ring system “A” palmerolides, it is 
confirmed that substructures within the side chain most definitely influence the efficacy 
of the compounds as well. Palmerolide D (0.002 µM), possessing the extended side 
chain, proves to be the most cytotoxic member of the series against melanoma followed 
by palmerolide A (0.024 µM) > palmerolide F (0.758 µM ) > palmerolide G (1.207 µM ) 
and the least cytotoxic of the group being palmerolide E (5 µM). The carboxamide 
moiety in the side chain appears to have a large impact on the bioactivity of this set of 
compounds overall since palmerolide E, lacking the entire carboxamide moiety, is devoid 
of activity against both UACC-62 cells and v-ATPase.  
Although the C-2’/C-3’ trisubstituted alkene does not appear to influence the 
cytotoxicity of these palmerolides the data suggest it may have some influence on v-
ATPase inhibition. Palmerolide F, which lacks the abovementioned trisubstituted olefin, 
is more cytotoxic than palmerolide G which possesses it. Interestingly, palmerolides A 
(0.002 µM), D (0.025 µM), and G (0.007 µM), all of which contain the C-2’/C-3’ olefin 
are very potent v-ATPase inhibitors whereas palmerolide F (0.063 µM) is significantly 
less potent. It is also interesting to note that the isomerization of the C-21/C-22 
trisubstituted olefin from the E-geometry to Z significantly affects the cytotoxicity of 
palmerolide G while barely affecting v-ATPase inhibiting ability. This data not only 
suggests that substructures within the side chain influence the overall bioactivity but also 
implies that different parts of the side chain are responsible for the activities exhibited 
against UACC-62 and v-ATPase. 
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Mother Nature did an exceptional job of illustrating the relationship between the 
structure and biological activity of the palmerolides. Bioassay of all of the compounds in 
the series allowed for the elucidation of the most pertinent structural features and 
provided a good starting point for further structure activity relationship studies (SAR). 
Collectively, this data establishes that the carboxamide moiety in the side chain is 
necessary for retaining overall bioactivity, but suggests that modificiation of 
substructures within the side chain and/or ring could possibly allow for the decoupling of 
v-ATPase activity from cytotoxicity. Palmerolides are less neurotoxic than other v-
ATPase inhibitors (unpublished data), leading us to believe that they bind more than one 
cellular target. The ratios shown in Table 11 were calculated in an effort to help prove or 
disprove the theory that the palmerolides may be binding multiple cellular targets.  It was 
anticipated that if some of the palmerolides lost considerable v-ATPase inhibiting activity 
while gaining significant cytotoxicity, particularly relative to palmerolide A, then the 
polymodal mechanism of action would be apparent in the ratios. If this were the case then 
a reciprocal ratio to that of palmerolide A would be expected. The closest example of this 
was found in palmerolides A and D, though the data is still inconclusive.  Additional 
SAR studies could provide more insight into the presumed polymodal mechanism of 
cytotoxicity in the palmerolides. 
 
2.3.2 Structure Activity Relationship Studies of Palmerolide A via Synthesis 
 In a recent publication, Nicolaou and coworkers shared their molecular design and 
chemical synthesis of several palmerolide A analogs.71 The biological evaluation of these 
compounds against a panel of cancer cells, including the UACC-62 melanoma cell line, 
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provided the first structure activity relationship studies to be performed on palmerolide 
A. In summary, their studies encompassed general structural modifications of the 
macrolide ring, the side chain, and the stereochemistry of palmerolide A. They observed 
that replacement of the C-11 carbamate with a hydroxyl group results in only a 5-fold 
decrease in activity, indicating the important role the carbamate functionality plays in 
palmerolide A’s activity against the UACC-62 cell line.  
Another important observation noted by Nicolaou et al. was that the deletion of 
the C-10 hydroxyl moiety significantly reduces the activity of palmerolide A, while 
deletion of the C-7 hydroxyl appears to have no effect. This finding warrants further 
investigation of these types of deoxygenated analogs in order to optimize the minimal 
natural product scaffold required to retain biological activity. It was also discovered that 
complete inversion of the molecules stereochemistry results in a 100-fold decrease in 
activity but inversion of a few stereocenters does not render it inactive. This finding is 
interesting because there are many instances in which mis-assignment of a single 
stereocenter in an active natural product can make the synthetic product devoid of 
pharmacological activity. The efforts of Nicolaou and coworkers toward the biological 
evaluation of synthetic palmerolide A analogs was extremely helpful because it enabled 
access to analogs that would not be possible through derivatization of the natural product. 
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2.3.3 Structure Activity Relationship Studies on Palmerolide A via Natural 
Product Derivatization  
 
2.3.3.1  Preparation of Palmerolide A analogs  
Six analogs (107-112) of palmerolide A were made through derivatization of the 
natural product. The first analog, 107, was made by hydrogenation of all alkenes in the 
molecule using H2 and palladium on activated carbon (10% Pd). The product was verified 
by acquisition of a full NMR data set and mass spectrometry. The absence of all alkenes 
was evident by the lack of olefinic signals in both the 1H (Figure 17) and 13C NMR 
spectra.  
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Figure 17. 1H NMR spectrum of palmerolide A hydrogenation product (107) 
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Analogs 108 and 109 are the C-7 and C-10 p-bromobenzoyl monoesters of 
palmerolide A. Both esters were made by the use of Hunig’s base, 4-bromobenzoyl 
chloride and N, N-dimethylaminopyridine. The disappearance of the C-7 and C-10 
hydroxyl protons were indications that the respective esters were formed as was the 
appearance of aromatic protons (Figure 18-19).  A shift of the oxymethines on the 
carbons bearing the esters was observed in both cases as well as a visible difference in the 
olefinic region for the C-10 monoester. Formation of the C-7/C-10 p-bromobenzoyl 
diester 110 was achieved by increasing the reaction time and the product confirmed by 
disappearance of both hydroxyl protons in addition to doubling of the aromatic signals 
(Figure 20). 
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Figure 18. 1H NMR spectrum of palmerolide A C-7 p-bromobenzoate (108)  
in d6-DMSO, 500 MHz 
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Figure 19. 1H NMR spectrum of palmerolide A C-10 p-bromobenzoate (109) 
in d6-DMSO, 500 MHz 
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Figure 20. 1H NMR spectrum of palmerolide A C-7/C-10 p-bromobenzoates (110) 
in d6-DMSO, 500 MHz 
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Palmerolide A was reacted with one equivalent of sodium methoxide to yield two 
major compounds, 111 and 112. Analog 111 is the C-11 carbamate hydrolysis product of 
palmerolide A and was verified by the disappearance of the carbamate signal in the 
carbon NMR spectrum as well as by the upfield shifts of H-10 and H-11 in the 1H NMR 
spectrum (Figure 21). Analog 112, the unexpected side product, is the result of the 
dehydration of the C-11 carbamate group and the conjugate addition of hydroxide to the 
C-3 position by what was thought to be a dry solution of sodium methoxide generated in 
situ.  The addition of hydroxide to the C-3 position as opposed to methoxide made it 
evident that water was present while trying to generate sodium methoxide from a solution 
of sodium hydroxide and dry methanol. The dehydration of the C-11 carbamate group 
was noted by the disappearance of the broad proton signal around 6.5 ppm (-NH2) as well 
as the absence of a carbon resonance at approximately 157 ppm in the 13C NMR 
spectrum. The conjugate addition of hydroxide was verified by the very obvious loss of 
the H-2 and H-3 olefinic protons in the 1H NMR spectrum along with the appearance of 
an additional resonance around 3.3 ppm that integrated to one proton (Figure 22). 
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Figure 22. 1H NMR spectrum of palmerolide A C-3 alcohol (112) 
in d6-DMSO, 500 MHz 
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 2.3.3.2  Biological Evaluation of Palmerolide A Analogs   
Each analog was evaluated for its cytotoxicity using a whole cell-based assay 
against UACC-62 melanoma cells (Table 12.). They were also evaluated for their ability 
to inhibit mammalian v-ATPase by the use of an in vitro enzyme-based assay which 
utilizes the bovine brain V-pump and the dissociated V0 sector (Table 12). Compound 
107, the fully hydrogenated palmerolide A product, was found to be void of activity 
against both UACC-62 and v-ATPase. This overall loss of activity is most likely caused 
by the removal of the features that provide the molecule its structural rigidity and much 
of its electronegativity. Indescriminate saturation of the alkenes in 107 prohibits us from 
determining which olefins are integral for retaining activity. Further SAR studies 
performing selective saturation of the ring olefins versus the side chain olefins could help 
narrow down which of the olefin(s) have the most bearing on the bioactivity. 
 
 
 
 
Compound 
vATPase 
(µM) 
Melanoma 
(µM) v-ATP:cytotoxicity ratio mammalian UACC-62
107 4.000 >10.000 > 0.400 
108 0.002 0.600 0.003 
109 0.014 0.309 0.045 
110 2.640 >10.000 > 0.264 
111 0.009 0.489 0.019 
112 0.026 0.850 0.030 
 
 
 
 
Table 12.  Bioactivity data for palmerolide A analogs (IC50 values) 
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Derivative 108, the C-7 p-bromobenzoyl ester, was found to be an equipotent 
inhibitor of v-ATPase in comparison to palmerolide A exhibiting an IC50 value of 2 nM 
but a significant decrease in cytotoxicity with an IC50 of 0.60 µM. This data indicates that 
the C-7 hydroxyl is not integral for retaining v-ATPase activity but does suggest that it 
may affect cytotoxicity. Unfortunately, it cannot be determined whether this observed 
decrease in cytotoxicity is a result of the significance of the C-7 hydroxyl or rather a 
decrease in cell membrane permeability due to the addition of a less polar substituent at 
the C-7 position. Since the assay for v-ATPase activity is enzyme-based the ability of the 
compound to cross the cell membrane is not an issue, whereas, the cytotoxicity assay 
requires the drug to first permeate the cell membrane before it can be evaluated for its 
ability to kill the cell.  
Furthermore, derivative 109, the C-10 p-bromobenzoyl ester, was incrementally 
less potent in v-ATPase inhibition (IC50 =14 nM) than 108 while roughly proportionally 
more cytotoxic (IC50= 0.31 µM).   This suggests that the C-10 hydroxyl is integral for v-
ATPase inhibition but does not clarify if the observed loss in activity is a result of 
masking the alcohol group so that the receptor binding is diminished or if the steric bulk 
of the benzoyl group restricts entry into the receptor. The cytotoxicity data implies that 
although it is still unclear whether or not cell permeability is an issue, the C-10 hydroxyl 
is not as critical as the C-7 hydroxyl for retaining activity. 
Although it appears as though the C-7 hydroxyl group is significant for retaining 
cytotoxicity and the C-10 hydroxyl group is significant for retaining v-ATPase inhibiton, 
it is not possible to distinguish from these limited examples whether or not the observed 
differences in activity are due to: 1) poor availability as a result of decreased cell 
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permeability, 2) masking the alcohol groups so that the receptor binding is diminished, or 
3) the steric bulk of the benzoyl group restricts entry into the receptor. Besides being 
sterically congested, derivative 110 is no doubt encumbered by significantly poorer 
solubility which accounts for the overall loss in activity. 
Hydrolysis of the carbamate group on palmerolide A (111) demonstrated little 
effect on v-ATPase inhibition (IC50= 9 nM) while significantly decreasing cytotoxicity 
(IC50= 0.49 µM). The reduced activity of this analog against the UACC-62 melanoma 
cell line has been previously reported by Nicolaou, but until recently no additional data 
has been acquired evaluating its inhibitory activity against v-ATPAse.68 The mild effect 
demonstrated  on the v-ATPase activity by removal of the carbamate moiety suggests that 
the carbamate moiety is not necessary to retain inhibition. The significant decreased in 
cytotoxicity, however, can  suggest that 111 is less adept at crossing the cell membrane or 
that more than one receptor interaction is responsible for cytotoxicity. Since the removal 
of the carbamate does not result in a significant difference in the compounds’ polarity the 
membrane permeability is expected to be minimally impacted by the structural 
difference. 
In compound 112, the removal of the α,β-unsaturated ester by the conjugate 
addition of hydroxide had a greater impact than anticipated on the bioactivity. 
Diminished cytotoxicity (IC50=0.84 µM) due to dehydration of the carbmate moiety was 
to be expected based on the effect observed for derivative 111 but it was interesting to 
note a decrease in v-ATPase inhbition as well (IC50=26 nM).  Drugs containing Michael 
acceptors such as α,β-unsaturated ester are notorious for undergoing alkylation in their 
metabolism which could explain the decrease in overall activity provided that cell 
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membrane permeability is not a issue. Taking the cytotoxicity data for the other analogs 
into consideration, it is quite possible that their bioactivity is achieved through a two-step 
process. The palmerolide must first bind to its molecular target then a nucleophile attacks 
the C-C double bond of the α,β-unsaturated ester which forms a covalent attached that 
activates the signals leading to cell death. 
Evaluation of the six palmerolide A analogs provided insightful data about the 
substructures necessary to retain bioactivity against both UACC-62 melanoma cell as 
well as mammalian v-ATPase, however, no connection was able to made between their 
cytotoxicity and their ability to inhibit the v-ATPase enzyme. The bioactivity ratios 
calculated in Table 12 for the palmerolide A analogs were just as inconclusive as those 
calculated for the other palmerolides in terms of confirming their polymodal mechanism 
of action. There are still many questions to be answered regarding the efficacy of 
palmerolide A as a potential drug but great strides have been made in determining the 
minimal chemical scaffold necessary to retain such activity. The SAR studies discussed 
in this dissertation along with those recently published by Nicolaou and coworkers 
provide a good starting point for further investigation. We are hopeful that at the very 
least, palmerolide A can be used as inspiration from nature in the form of a chemical 
scaffold for future drug candidates. 
 
 
  
 
CHAPTER THREE: 
Glycosphingolipids from Synoicum adareanum 
 
3.1 Introduction to Glycosphingolipids 
Glycosphingolipids are a group of amphipathic membrane lipids comprised of 
two main structural units: a sugar and a ceramide, and are important components of the 
cell membranes of plants and animals (Figure 21). The hydrophilic saccharide portion 
consists of either a simple or complex carbohydrate, and the hydrophobic ceramide 
portion consists of an amide-linked fatty acid chain bound to a sphingosine base. 
Compounds from this class have demonstrated a broad range of bioactivity which is 
postulated to arise from their amphipathic nature. Immunomodulating,72,73 cytotoxic,74-76 
antimicrobial,76-78 antifungal,77 antiviral and ionophoric activity for Ca2+ ions,79,80 and are 
among their recently discovered biological activities. 
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Figure 23. Basic structural units of glycosphingolipids  
(a) saccharide, (b) fatty acid, (c) sphingosine base 
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The isolation of glycoshingolipids and their derivatives from marine sources 
including sponges,81-83 tunicates,84,85 sea stars,86-90 and sea anemones91,92 has been 
reported although many do not disclose bioactivity. Due to the amphipathicity of these 
compounds and their propensity to exist as homologues, their separation and structure 
elucidation has proven arduous.  
 
3.2 Isolation of Glycosphingolipids from Synoicum adareanum 
In our chemical investigation of the Antarctic tunicate Synoicum adareanum, a 
number of glycosphingolipids have been isolated from the more polar fractions of the 
organic extract (Scheme 1). Freeze-dried tunicate was extracted three times over a 
seventy-two hour period with a 1:1 methanol:dichloromethane solution to generate a 
crude organic extract, replacing with just enough fresh solvent to cover the organism 
every twenty-four hours. The organism was extracted in the same manner using a 1:1 
water:methanol solution to produce a crude aqueous extract. The organic extracts were 
combined and concentrated in vacuo. The crude organic extract was dissolved in a 
mixture of 1:1 water:ethyl acetate and transferred into a separatory funnel to be 
partitioned. The aqueous layer was rinsed several times with ethyl acetate and the organic 
layers combined. The combined organic layers were subsequently dried over anhydrous 
magnesium sulfate. Filtration was used to remove the drying agent and the organic 
partition was concentrated in vacuo. This extract was subjected to flash chromatography 
using silica gel with an ethyl acetate:methanol gradient solvent system resulting in ten 
fractions, with the glycoshingolipids eluting at the more polar end of the gradient around 
8-10% MeOH/EtOAc. These fractions were purified by repeated high 
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pressure/performance liquid chromatography (HPLC) using both normal phase silica gel 
and reversed phase C-18 columns to afford a crude glycolipid mixture. 
 
Scheme 1. The extraction of Synoicum adareanum 
 
Freeze Dried Tunicate (0.523 kg)
Extracted w/ 1:1 CH2Cl2/MeOH (~67 g) Extracted w/ 1:1 MeOH/H2O (~130 g)
Partitioned with EtOAc/H2O
Dried EtOAc layer
and conc. in vacuo
(19.41 g)
Conc. aqueous layer
in vacuo
(47.62 g)
Ran on SiO2 column with an increasing
polarity gradient of EtOAc/MeOH
100% EtOAc (~4711 mg)
1% MeOH/EtOAc (~1588 mg)
100% MeOH (~110 mg)
2% MeOH/EtOAc (~171 mg)
50% MeOH/EtOAc (~8.2 mg)
4% MeOH/EtOAc (~156 mg)
6% MeOH/EtOAc (~380 mg)
8% MeOH/EtOAc (~132 mg)
10% MeOH/EtOAc (~1609 mg)
20% MeOH/EtOAc (~10.7 mg)
Partitioned with n-BuOH/H2O
Dried n-BuOH layer
and conc. in vacuo
(~33 g)
Conc. aqueous layer
in vacuo
(~100 g)
glycosphingolipids
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The crude mixture was acetylated with acetic anhydride and pyridine then 
purified by repeated HPLC on silica columns using n-hexane:ethyl acetate and n-hexane: 
isopropanol.90 Two fractions, each of which contained a mixture of peracetylated 
glycosphingolipids, were obtained followed by subsequent deacetylation with sodium 
methoxide in methanol to afford the natural products.90 A reversed phase HPLC 
separation gave rise to two series of homologous glycosphingolipids, 113a-d and an 
inseparable mixture of 114a-b. 
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3.3 Structure Elucidation of Glycosphingolipids from S. adareanum  
Analysis of the NMR data acquired for 113a revealed that it contained distinct signals 
characteristic of a sugar, a fatty acid chain, and an amide linkage strongly suggesting that 
the compound was a glycosphingolipid (Figure 22). The structure of 113a was elucidated 
starting at the amide nitrogen (δ7.41), which could be correlated to the attached carbonyl 
(δ175.7) and alpha hydroxyl-bearing C-2” (δ71.6) by gHMBC. A series of gCOSY 
correlations allowed for the assignment of methylenes C-3” (δ 35.2) and C-4” (δ25.4), 
which appeared to be the beginning of a fatty acid chain. The chain extended from C-5” 
(δ29.5) onward and consisted of an unknown number of coincident methylenes (δ29.5) 
with the proton chemical shift δ1.24 and ended with the C-18” methyl (δ0.84). The length 
of the alkyl chain remained to be established and would later be determined by mass 
spectrometry.  
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Figure 24. 1H NMR spectrum of glycosphingolipid 113a in d6-DMSO, 500 MHz 
The C-2 (δ53.5) carbon of the shingosine base was confirmed to be on the other side 
of the amide linkage based on gHMBC correlations to the C-1” amide carbonyl (δ175.7) 
and gCOSY correlations to the amide proton (δ7.41). A oxymethine (δ70.6) could be 
placed adjacent to C-2 by gCOSY followed by a trans disubstituted olfefin (JH,H= 15.6 
Hz) located between C-4 (δ131.1) and C-5(δ130.0). Two methylenes were found to 
separate the C-4/C-5 olefin from a C-8 (δ129.2)/C-9 (δ133.0) methyl branched, 
trisubstituted olefin which was conjugated to another trans disubstituted olefin (JH,H= 
15.6 Hz) positioned between C-10 (δ135.4) and C-11(δ127.1). The trisubstituted olefin 
was assigned as having E geometry based on a ROESY correlation between H2-7 (δ2.13) 
and H3-19 (δ1.64). The remainder of the sphingosine moiety consisted of a seven carbon 
alkyl chain, with clear gHMBC and gCOSY correlations to each of the carbons allowing 
for their assignment without the use of mass spectroscopic data. A search of the chemical 
literature revealed this 4,8,10- triunsaturated, 9-methyl branched sphingoid base to be 
common among the sphingolipids isolated from marine invertebrates. 
The sugar moiety was determined to be attached to the ceramide by gHMBC 
correlations from H-1’ (δ4.12) to C-1 (δ69.3) and C-2 (δ53.5). The anomeric proton was 
identified from its gHSQC correlation to the anomeric carbon at δ104.2 ppm. After the 
anomeric proton was identified the other 1H and 13C NMR signals of the sugar could be 
assigned using the gCOSY and gHSQC data. The gluco configuration of the sugar as well 
as its β anomeric configuration was established based on a comparison of the ring proton 
coupling constants (Table 22) to the literature values of previously identified 
glycospingolipids.90,93 
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 Coupling Angle (ɸ) J-value (Hz) 
axial/axial 180 8-14 Hz 
axial/equatorial 60 1-7 Hz 
equatorial/equatorial 60 1-7 Hz 
ɸ = 60 
ɸ = 180 
β - form α - form 
Table 22. Calculated coupling constants of sugar protons 
 
 
 
 
 A comparison of the chemical shifts of the sugar protons in deuterated pyridine to 
those of the previously isolated oreacerebrosides,90 which are known to contain either a 
glucopyranose or galactopyranose residue, suggested that compound 113a was a 
glucosphingolipid. Further analysis by comparison of the vicinal proton coupling 
constants confirmed this assignment. A large coupling constant (J1,2 = 7.7 Hz) was 
observed for the vicinal coupling of H-1’ and H-2’ of the sugar, indicating that the two 
protons were axial and therefore establishing that the sugar was in the β-conformation 
(Table 22). The vicinal coupling of H-2’ and H-3’ was also large (J2,3 = 8.5 Hz), which 
showed that H-1’, H-2’ and H-3’ were all axial. A large J-coupling value (J3,4 = 9 Hz) 
between H-3’ and H-4’ confirmed that the saccharide was in fact a glucopyranose 
residue, because a small J3,4 coupling constant would have been observed if a 
galactopyranose residue was present due to the  equatorial H-4’ (Figure 23). 
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 Figure 25. Comparison of β-galactopyranoside and β-glucopyranoside 
 
Analysis of the APCI MS data showed an [M+Na]+ pseudomolecular ion for 
compound 113a of 776 m/z , and a parent ion [M + 1]+ of 754 m/z, along with insightful 
fragmentation. An [M-162]+  peak of 591 m/z was observed due to the cleavage of the 
sugar unit as well as an [M-470]+ peak of 283 m/z that accounted for the loss of a C18  2-
hydroxy fatty acyl group (with transfer of one H atom to the sphingosine). These 
fragments confirmed that the sphingosine base contained seventeen carbons as was 
postulated from the NMR data and that the 2-hydroxy chain consisted of eighteen 
carbons.  A search of the chemical literature revealed that compound 113a was a 
previously isolated glucosphingolipid from the ascidian Phallusia fumigata called 
phalluside 2.84 
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 Figure 26. The most characteristic fragment ions in 
the APCI -MS data of glycosphingolipid 113a  
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The other three glycosphingolipids (113b-d) were determined to be homologous 
to 113a based on a comparison of their 1H NMR data and their similar chromatographic 
properties. Compounds 113b-d were all found to contain a glucose sugar residue, and a 
ceramide composed of the same 4,8,10- triunsaturated, 9-methyl branched sphingoid base 
and 2-hydroxy fatty acid. The only portion of the molecules that remained unassigned 
was the length of the alkyl chain of the fatty acid. Mass spectral analysis using APCI as 
the ionization method revealed that the alkyl chains of the three glucosphingolipids 
differed from each other by only a single methylene. 
 Compound 113b showed an [M + Na]+ of 790 m/z indicating that it had a 
molecular weight of 767 g/mol and formula of C44H81NO9 . Fragmentation of the sugar 
from the ceramide portion resulted in a loss of 162, resulting in an [M + Na – 162]+ of 
628 m/z. This peak revealed that the fatty acid portion of the ceramide contained one 
more methylene than compound 113a. A fragmentation peak of moderate intensity was 
observed at 610 m/z, accounting for the cleavage of the sugar unit as well as the 
dehydration of one of the alcohols of the ceramide ([M + Na – 180]+).  
 Compound 113c demonstrated an [M + Na]+ of 804 m/z indicating a molecular 
weight of 781 g/mol and molecular formula of C45H83NO9. An [M + Na – 162]+ of 642 
m/z was observed for the loss of the sugar unit and an [M + Na – 180]+ for the loss of the 
sugar unit and dehydration of a hydroxyl group. Analysis of the mass spectrometric data 
revealed that the fatty acid chain of 113c contained one more methylene than 113b. 
 Compound 113d had a [M + Na]+  pseudomolecular ion peak at 818 m/z and an 
[M + Na – 162]+ of 656 m/z for the cleavage of the glucose residue. The usual [M + Na – 
180]+  was observed at 612 m/z for the dehydration of a hydroxyl from the precursor ion 
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[M + Na – 162]+. The molecular formula was established as C46H85NO9, indicating that 
the alkyl chain of the fatty acid consisted of one more methylene than 113c.  
 A comparison of the 1H NMR spectra of compounds 114a and 114b (Figure 25) to 
those of 113a-d showed that they were clearly two different series of glycosphingolipids. 
It was evident from the 1H NMR spectrum that 114a and 114b had fewer olefins, with the 
absence of the H-10 (δ6.00) proton being particularly apparent. Further analysis revealed 
the absence of the C-19 olefinic methyl of the C-8/C-9 trisubstituted olefin as well based 
on the disappearance of the intense singlet at δ1.64 ppm. The proton NMR spectrum 
suggested that the C-8/C-9 trisubstituted olefin was not present either because of the 
disappearance of the H-7 (δ2.13) proton, which was originally shifted further downfield 
than the other methylenes because it was between to unsaturated systems.  A full NMR 
data set of the inseparable mixture of 114a and 114b confirmed that the C-4/C-5 
disubstituted alkene was the only unsaturation present in the molecule. Performing a 
cursory evaluation of the chemical shifts and general splitting pattern of the sugar protons 
to those of compounds 113a-d strongly suggested that the saccharide residue was a 
glucopyranoside. Unfortunately, due to the limited amount of sample isolated an optimal 
proton NMR spectrum could not be obtained in order to extract all of the coupling 
constants.                                                                                                                                                        
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 Figure 27. 1H NMR spectrum of glycosphingolipid 114a-b in d6-DMSO, 500 MHz 
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 With the general structure of the glucosphingolipid backbone established the only 
remaining structural features to be assigned were the number of carbons in both the fatty 
acid chain and sphingosine base. Unlike the first series of compounds isolated, all of the 
carbons of the sphingosine unit could not be identified by NMR spectroscopy. Mass 
spectrometric data was utilized in order to determined the number of carbon atoms in the 
ceramide portions of both 114a and 114b, however, it provided no insight into how they 
were distributed amongst the sphingosine and fatty acid.  
  Compound 114a showed an [M + Na]+  pseudomolecular ion of 738 m/z, indicating 
a mass of 715 g/mol and a molecular formula of C40H77NO9. Dehydration of the 
saccharide resulted in an [M + Na – 162]+ of 576 m/z meaning that the ceramide 
contained 34 carbon atoms. A dehydration of one of the alcohols was observed with an 
[M + Na – 180]+ at 558 m/z. Compound 114b exhibited an [M + Na]+  of 752 m/z and an 
[M + Na – 162]+ of 590 m/z signifying that the ceramide moiety contained 35 carbon 
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atoms, which was one more methylene than 114a. An [M + Na – 180]+   of 572 m/z 
arising from the loss of an alcohol from the ceramide was observed as it had been for all 
of the other glucosphingolipids isolated from S.adareanum. Although the mass 
spectrometric data was helpful in discerning the number of carbon atoms present in the 
ceramide, more advanced measures will have to be taken in order to determine their 
distribution between the two components of the ceramide. Literature precedence suggests 
that either hydrolysis of both the saccharide and the amide or tandem mass spectrometry 
can be used to achieve this. 
A search of the chemical literature for compounds similar to those discussed 
above resulted in quite a few compounds with the same general structure, many of them 
originating from marine organisms, but suggests that compounds 113b-d as well as 114a-
b are new glucosphingolipids. Future isolation of these compounds in higher yields is 
necessary in order to obtain the necessary physical data for publication and biological 
evaluation. 
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CHAPTER FOUR: 
Anti-leishmanial Sterols from the Orange, Encrusting 
Antarctic Sponge Artemisina plumosa 
 
4.1 Introduction to Leishmania 
 Leishmaniasis is a group of neglected tropical diseases caused by twenty species 
of protozoan parasites of the genus Leishmania and are transmitted by thirty species of 
sandfly.94 These diseases afflict eighty-eight countries, all in tropical or temperate 
regions, with an infection rate of approximately two million men, women, and children 
each year.95 The species of Leishmania are divided according to their geographic location 
of endemic species and are designated as either Old World (Eastern Hemisphere) or New 
World (Western Hemisphere). The primary reservoir hosts for all Leismania spp. are 
vertebrates such as rodents, canids, marsupials, and humans, however, the parasite is 
carried by the female phlebotamine sandfly of the genus Phlebotamus in the Old World 
and Lutzomyia in the New World.96 
 Infection by Leishmania spp. results in three clearly distinguishable clinical 
manifestations regarded as visceral, mucocutaneous, and cutaneous.97 In general, the 
visceral form is the most deadly and affects some of the internal organs, the 
mucocutaneous form affects the skin and mucous membranes, and the cutaneous form 
affects the skin. Approximately ninety percent of visceral infections have been found to 
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occur in Brazil, Bangladesh, India, Nepal and Sudan.96 Mucocutaneous infections are 
prevalent in Brazil, Peru, and Bolivia; whereas cutaneous infections are prevalent in 
Afghanistan, Brazil, Iran, Peru, Saudi Arabia and Syria.96 
 There is no vaccine to prevent infection by Leishmania spp. instead there are only 
a few conventional drugs that have been used to treat the infections.96 These drugs are not 
only expensive but the parasites are quickly developing a resistance to them and they 
have several side effects.98 For these reasons, the search for new anti-leishmanial drugs is 
of paramount interest to medicinal chemists. Natural products have recently been found 
to be potential sources for the treatment of a number of tropical diseases caused by 
protozoans and other parasites.96,99,100 Many anti-leishmanial natural products have been 
discovered from the marine realm such as renieramycin A (115) from the Japanese marine 
sponge Neopetrosia sp.,101 euplotin C (116) from the marine ciliate protist Euplotes 
crassus,102 and isoakaterpin (117) from the sponge Callyspongia sp.103 These compounds 
have been of particular interest to our laboratory because of the implications they have 
for our research. Literature precedence that validated marine secondary metabolites as 
potential anti-leishmanial agents prompted a new collaboration to be made between our 
natural products laboratory and one with the ability to perform high-throughput screening 
against Leishmania spp. parasites. 
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In an effort to contribute to the search for new and more cost effective treatments 
for leishmaniasis our laboratory has screened over 800 extracts of Antarctic marine 
organisms against Leishmania donovani. Only 13 of these crude extracts demonstrated 
inhibitory activity against the parasite. For many of the extracts, anti-leishmanial activity 
was lost upon separation, indicating a synergistic relationship amongst its components. 
However, the organic extract of the orange, encrusting sponge Artemisina plumosa 
demonstrated a significant increase in inhibition upon separation.  
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4.2 Bioassay-guided fractionation of Artemisina plumosa 
 Freeze-dried sponge was extracted three times for a period of 24 hours in a 1:1 
solution of dichloromethane:methanol, after which the organic extracts were combined 
and concentrated. The crude organic extract was subjected to separation via MPLC using 
a normal phase silica gel pre-packed column and a tertiary gradient from 100% hexanes 
to 100% ethyl acetate then to 100% methanol. Bioassay of these initial fractions allowed 
for the identification of the fraction responsible for the originally observed activity. A 
proton NMR spectrum of this fraction indicated that it consisted mainly of a sterol(s). 
The sterol-containing fraction was separated a number of times using HPLC, alternating 
between normal and reversed phase to separate sterols by differences in both their rings 
and side chains. When it appeared that a pure compound was obtained based on 1H NMR 
data and TLC, a full NMR data set was acquired only to reveal that the sample was 
comprised of more than one sterol with very closely related structures. Of these 
inseparable mixtures, three general steroidal skeletons were identified all of which 
contained an exomethylene in the side chain. The least polar of the steroids were a series 
of steroidal ketones with the general structure shown in Figure 26, containing a single 
unsaturation independent of the side chain exomethylene. Two dimensional NMR data 
suggested that this unsaturation was located on the side chain as well. The second series 
was a group of sterols with what appeared to be an unsaturation in the B-ring in addition 
to the exomethylene (Figure 27). And the third series were sterols with unsaturations in 
both the B-ring and the side chain as well as the exomethylene (Figure 28). 
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Figure 28. 1H NMR spectrum of steroid series 1 in CDCl3, 600 MHz  
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Figure 29. 1H NMR spectrum of steroid series 2 in CDCl3, 500 MHz  
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Figure 30. 1H NMR spectrum of steroid series 3 in CDCl3, 500 MHz 
  
Each of the steroid skeletons were tested against the Leishmania donovani 
parasites in order to determine which of the three was most responsible for the observed 
bioactivity as well as to prioritize the order in which to move forward with the fractions. 
The results revealed that all three steroidal skeletons were active against the parasites but 
there was only a slight difference observed in their activity. The keto-steroid (Figure 26) 
demonstrated an IC50 of 5 μg/mL, the doubly unsaturated sterol (Figure 27) demonstrated 
an IC50 of 4 μg/mL, and the sterol containing three unsaturations (Figure 28) was the 
most active demonstrating an IC50 of 3.5 μg/mL. 
 A literature search for other sterols possessing anti-leishmanial activity showed 
sterols that also contain an exomethylene group in the side chain (118-123). Clerosterol 
(118)104 was isolated from the fruits of Cassia fistula and the norselic acids (119-123) 
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from the Antarctic sponge Crella sp.105 A superficial comparison of these sterols 
indicates that the basic four ring steroid skeleton and the exomethylene group in the side 
chain are the only structurally features that all of them have in common. Since not all 
steroids possess anti-leishmanial activity it can be postulated that the exomethylene plays 
an important role in the steroids bioactivity. 
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A search of the chemical literature for other sponges of the Artemisina genus 
surprisingly revealed that the chemical investigation of only one other sponge from the 
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genus had been reported. The Antarctic sponge Artemisina apollinis was found to 
elaborate twenty-eight C25-C30 sterols as well as a few steroidal ketones, all of which 
were separated using argentation chromatography and characterized by GC-MS.104 The 
complex mixture was able to be broken down into four steroidal nuclei and twelve side 
chains (Figure 29).106 
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Figure 31. Steroid nuclei and side chains found in Artemisina apollonis 
 
 The variety and distribution of steroids found in A. apollonis are very similar to 
those observed in the collection of Artemisina plumosa currently being studied in our 
laboratory and suggests that an unusually high number of sterols may be present in this 
fellow Antarctic sponge as well. At least two other sponges in the literature also report a 
large number of sterols elaborated with the same general variation in steroidal nuclei and 
side chains.107,108 These closely related metabolites were also separated using more 
advanced methods of chromatography and characterized by GC-MS. 
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 It appears that further separation of the sterol-containing fractions of A. plumosa 
is plausible using the methodologies reported in other papers for sponges containing such 
a large number of closely related sterols. However, it should be noted that the authors of 
these papers were only able to isolate a few pure sterols if any while the others were 
characterized strictly by GC-MS. In many instances, sterols were derivatized as their 
sterol acetates and separated by argentation chromatography to aid in further separation 
than that achieved using the usual normal and reversed phase conditions.104-107 The sterol 
acetates were then deacetylated and cleaned up using reversed phase HPLC. Although 
this method has the ability to provide additional separation of the sterols based on the 
number and location of the unsaturations the difficulty remains in separating those that 
only differ in alkyl substitution.  
There is still a great deal of research to be done on this Antarctic sponge and it 
should be continued for many reasons. Further chemical investigation will hopefully lead 
to a detailed account of its many substituents which is important since only one other 
sponge of the Artemisina genus has been chemically investigated to date. In addition, the 
search for new treatments of leishmaniasis remains a pressing issue and natural products 
still appear to be an underestimated and untapped source of anti-infective agents.  
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CHAPTER FIVE: 
Conclusion 
 
 The chemical investigation of the Antarctic tunicate Synoicum adareanum has led 
to the isolation of a number of secondary metabolites that have yet to be fully evaluated 
for their biological activities. The palmerolides have proven to be potent inhibitors of v-
ATPase as well as selectively cytotoxic against UACC-62 melanoma cells, and are 
anticipated to operate by a polymodal mechanism of action. Preliminary structure activity 
relationship studies have provided insight into the structural features necessary to retain 
cytotoxicity and v-ATPase inhibition but have failed to decouple the bioactivities from 
one another. It is anticipated that further studies into their mechanism of action will 
reveal that they bind to multiple receptors. Determining their binding site(s) will be the 
next step towards making the palmerolides plausible drug candidates. The stereochemical 
assignment of the palmerolides described in this dissertation is significant because 
complete characterization is necessary in order to move them into the next stage of drug 
discovery and it also allows for the total synthesis of these compounds in order to access 
them from another route than the natural source.  
 S. adareanum was also found to elaborate a series of glucosphingolipids but they 
were isolated in such small quantities that bioassay and complete characterization was not 
possible. Extracting a larger amount of the tunicate will lead to the isolation of these 
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compounds in greater quantitites which would allow for the acquisition of the necessary 
physical data as well as to provide enough sample to submit to a number of assays that 
similar compounds have shown activity in.  
 The Antarctic orange, encrusting sponge Artemisina plumosa was separated by 
bioassay-guided fractionation against Leishmania donovani which revealed that it 
produces a number of anti-leishmanial sterol and steroidal ketone constituents. Continued 
fractionation will lead to pure compounds that can be further evaluated as potential anti-
leishmanial treatments. The search for treatments for leishmaniasis that are cheap and 
easy to administer is still underway and marine natural products are recently proving to 
be a potential source.  
 The chemical investigation of both of these marine invertebrates has led to the 
discovery of a number of bioactive metabolites that warrant further investigation into 
their activity. The research discussed in the following chapters describes our efforts to 
contribute to both the field of natural products chemistry and drug discovery through the 
chemical investigation of Antarctic organisms. Although there is still a great deal of work 
to be done on these projects, significant contributions have been made and described in 
this dissertation. 
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CHAPTER SIX: 
Experimental 
 
6.1  General Experimental Procedures 
Optical rotations were measured on a Rudolph Research Analytical AUTOPOL® 
IV digital polarimeter. IR and UV spectra were measured on a Nicolete Avatar 320FT 
infrared and a Hewlett-Packard 8452A diode array spectrophotometer, respectively. 
NMR spectra were recorded on Varian Inova 500 MHz and 600 MHz instruments. 
Chemical shifts are give as δ (ppm) with TMS as internal standard. The low resonance 
mass spectra were recorded on an Agilent Technologies LC/MSD VL electrospray 
ionization mass spectrometer. The high resonance mass spectra were recorded on an 
Agilent Technologies LC/MSD TOF electrospray ionization spectrometer. Flash column 
chromatography was carried out on EM Science silica gel 60 of 230-400 mesh. High 
performance liquid chromatography was carried out on preparative YMC-Pack ODS-AQ 
reverse phase columns (250 x 20 mm) and analytical columns (250 X 10 mm) using an 
LC-8A Shimadzu multi-solvent delivery system, an SCL-10A Shimadzu system 
controller, and an SPD-10A Shimadzu UV-Vis detector. 
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6.2  Biological Material   
The tunicate Synoicum adareanum and sponge Artemisina plumosa was collected 
by hand using SCUBA near Palmer Station on the Antarctic Peninsula between 2000-
2008. The specimens were immediately frozen and kept frozen until extraction. A 
voucher specimen of the tunicate was identified by Dr. Linda Cole at the Smithsonian 
Institution, Washington, D.C. and the sponge identified by Dr. Rob van Soest at the 
Instituut voor Taxonomische Zoologie, Amsterdam, The Netherlands. 
 
6.3 Extraction of S. adareanum and Isolation Secondary Metabolites 
Freeze dried S. adareanum was extracted with CH2Cl2/MeOH. The combined 
extract was concentrated and the residue was partitioned between EtOAc and H2O. 
Subsequently, the EtOAc layer was dried with MgSO4 and concentrated in vacuo.  The 
crude organic extract was subjected to flash column chromatography using a binary 
gradient of EtOAc/MeOH to give ten fractions. The less polar (1%-6% MeOH/EtOAc) of 
the fractions were further separated using 40% H2O/MeCN, and the palmerolide-
containing fractions obtained from the separation were double purified using 20-30% 
H2O/MeOH to afford pure palmerolides A, C, D, E, F, G and K. The more polar fractions 
(20%-50% MeOH/EtOAc) were further purified using 50% H2O/MeCN, and the 
palmerolide-containing fractions obtained from the separation were double purified using 
50% H2O/MeOH to afford pure palmerolides B and H. The glycoshingolipids eluted 
toward the middle of the gradient around 8-10% MeOH/EtOAc. These fractions were 
separated by repeated high pressure/performance liquid chromatography (HPLC) using 
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repeated normal phase silica gel and reversed phase C-18 columns to afford a crude 
glycolipid mixture. 
 
Palmerolide B (96) : white solid; [α]D25= + 1.6 (c = 0.1, MeOH); UV/Vis (MeOH): λmax 
(ε)= 216 (1756), 240 (603); IR (thin film):  3514, 3433, 1648, 1633, 1510, 1392, 1275, 
1190 cm-1; LR ESIMS (-) m/z 663.3[M - H]-, LR ESIMS (+) m/z 567.3 [M + H - 
H2SO4]+, HR ESIMS (-) m/z 663.29417 (C33H47N2O10S requires. 663.29569), HR ESIMS 
(+) m/z 567.3430 (C33H46N2O6 requires 567.3429); 1H and 13C NMR, see Appendices A-3 
and B-33. 
 
Palmerolide C (97): white solid; [α]D25= - 27.1 (c = 0.1, MeOH); UV/Vis (MeOH): λmax 
(ε): 216 (1002), 248 (635); IR (thin film):  3364 (br), 2933, 1697, 1637, 1446, 1387, 
1274, 1182, 1018, 978 cm-1; LR ESIMS (+) m/z 608.3 [M + H + Na]+, HR ESIMS (+) 
m/z 585.3534 (C33H49N2O7 requires 585.3540); 1H and 13C NMR, see Appendices A-4 
and B-58. 
 
Palmerolide D (98): colorless solid; [α]D25= +67 (c = 0.5, MeOH); UV/Vis (MeOH): λmax 
(ε): 216 (1742), 248 (528);  IR (thin film): 3327, 2939, 2829, 2061, 1716, 1558. 1455, 
1261, 1025, 975 cm-1; LR ESIMS (+) m/z 625.6, HR ESIMS (+) m/z 625.3864 
(C36H53N2O7 requires 625.3853); 1H and 13C NMR, see Appendices A-1 and B-1. 
 
Palmerolide E (99): colorless solid, [α]D25= +17 (c= 0.1, MeOH); UV/Vis (MeOH): λmax 
(ε): 216 (1295), 248 (645); IR (thin film): 3635, 2940, 2830,1715, 1637, 1540, 1387, 
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1276, 1194, 1079, 938 cm-1; LR  ESIMS (+) m/z 601.5, HR ESIMS (+) m/z 512.2634 
(C27H39NO7Na requires 512.2624); 1H and 13C NMR, see Appendices A-1 and B-9. 
 
Palmerolide F (100): yellow solid; [α]D22= -67.1 (c= 0.5, MeOH); UV/Vis (MeOH): λmax 
(ε)= 213 (413), 262 (229); IR (thin film) 3340, 3013, 1705, 1642, 1524, 1318, 1216, 
1187, 1018, 976 cm-1; LR ESIMS (+) m/z 607 [M + Na]+; HR ESIMS (+) m/z 607.3359  
(C33H48N2O7Na requires 607.3359); 1H and 13C NMR data, see Appendices A-2 and B-
17. 
 
Palmerolide G (101):  yellow solid; [α]D22= -27.1 (c= 0.1, MeOH); UV/Vis (MeOH): 
λmax (ε)= 216 (719) , 262 (403); IR (thin film) 3383, 2927, 1705, 1638, 1522, 1457, 1377, 
1279, 1216, 1194, 1024 cm-1; HR ESIMS [M + Na]+ m/z 607.3350  (C33H48N2O7Na 
requires 607.3359) 1H and 13C NMR data, see Appendices A-2 and B-26. 
 
Palmerolide H (102): colorless solid, [α]D25= -27 (c= 0.1, MeOH); UV/Vis (MeOH): 
λmax(ε) = 217 (1232), 248 (712); IR (thin film) 3515, 3400 (br), 2925, 2856, 1653, 1633, 
1517, 1208, 1040 cm-1; LR ESIMS (-) m/z 703.3 [M - H]-, LR ESIMS (+) m/z 607.3 [M + 
H – H2SO4]+, HR ESIMS m/z 703.3258 (C36H52N2O10S  requires 703.3270); 1H and 13C 
NMR, see Appendices A-3 and B-49. 
 
Palmerolide K (104): yellow solid, [α]D22= -30.1 (c= 0.1, MeOH); UV/Vis (MeOH): 
λmax (ε) = 216 (1492), 262 (705); IR (thin film): 3383, 2927, 1707,1379, 1215, 1025 cm-1; 
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LR ESIMS (+) m/z 534 [M + HCOO]-, HR ESIMS (+) m/z 534.2704 (C28H40NO9 
requires 534.6190); 1H and 13C NMR, see Appendices A-4 and B-69. 
 
6.4 Acetylation of the Glycosphingolipids from S. adareanum 
The crude glycolipid-containing fraction was acetylated with Ac2O in pyridine at 
25 °C for 18 h. The reaction mixture was separated by repeated HPLC on silica columns 
using n-hexane/ethyl acetate and n-hexane/isopropanol. Two fractions, each of which 
contained a mixture of peracetylated glycosphingolipids, were obtained and subsequently 
deacetylated by dissolving each fraction in MeOH and adding a solution of MeONa in 
MeOH (0.4 M). The reaction was allowed to proceed for 18 h at 25 °C after which the 
crude reaction mixtures were concentrated and partitioned between chloroform and 
water. The organic layers were concentrated and purified by reversed phase HPLC using 
C-18 and a gradient from 20% H2O/MeOH to 100% MeOH. The first fraction injected 
contained glycosphingolipids 113a-d, which eluted towards the end of the gradient in the 
order of their lipophilicity as was to be expected (113aÆ113d). The longer the fatty acid 
side chain the higher the concentration of MeOH necessary for it to elute from the 
column. The second fraction injected contained glycosphingolipids 114a-b and resulted 
in an inseparable mixture of the two. Glycosphingolipids 113a-d were purified on a 
normal phase HPLC column using 20% MeOH/CH2Cl2. 
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6.5 Preparation of Palmerolide A Analogs 
 
6.5.1   Preparation of 107.  Palmerolide A was dissolved in methanol and 
subsequently transferred into a round bottom flask to be concentrated in vacuo. It was 
then dissolved in a minimal amount of methanol (1-2 drops) and then diluted to half of 
the volume of the reaction flask with ethanol. A magnetic stir bar and activated Pd/C was 
added to the flask followed by the attachment of an H2 (g) balloon to the mouth of the 
flask. The reaction was allowed to stir for 24 hours at rt and quenched with ethyl acetate. 
The crude reaction mixture was filtered over Celite. The filtrate was concentrated then 
purified on an analytical reverse phase C18 HPLC column using 100% MeOH. 
 Compound 107: Clear oil, [α]D30= -3.5 (c = 0.4, CDCl3); UV/Vis (MeOH): λmax= 211 
(341), 300 (86). 1H NMR (500 MHz, d6-DMSO) δ 7.71 (1H, m, 24-NH), 6.31 (1H, br s, 
OCONH2), 4.85 (1H, m, H-19), 4.49 (1H, m, H-11), 3.43 (1H, m, H-10), 3.38 (1H, m, H-
7), 3.07 (2H, m, H2-24), 2.27 (2H, m, H2-2’), 2.17 (2H, m, H2-2), 1.92 (1H, s, H-3’), 1.64 
(1H, m, H-20), 1.52 (2H, m, H2-23), 1.51 (1H, m, H-12a), 1.47 (2H, m, H2-9), 1.47 (1H, 
m, H-18a) 1.38 (1H, m, H-12b), 1.36 (2H, m, H2-8), 1.36 (1H, m, H-22), 1.32 (1H, m, H-
18b), 1.30 (1H, m, H-17), 1.26 (2H, H2-3, H2-4, H2-5, H2-6, H2-13, H2-14, H2-15, H2-16), 
1.07 (2H, m, H2-21), 0.84 (3H,s, H3-4’), 0.84 (3H, s, H3-5’), 0.80 (3H, s, H3-27), 0.80 
(3H, d, H3-26), 0.80 (3H, s, H3-25); 13C NMR (125 MHz, d6-DMSO) δ 173.4 (C-1), 171.9 
(C-1’), 157.7 (OCONH2), 75.78 (C-11), 74.7 (C-19), 71.8 (C-7), 70.5 (C-10), 45.6 (C-3’), 
40.0 (C-24), 37.7 (C-22), 36.9 (C-23), 34.8 (C-2), 34.3 (C-2’), 28.5-30.0 (C-3,C-4, C-5, 
C-6, C-8, C-9, C-12, C-13, C-14, C-15, C-16, C-17, C-18, C-20, C-21), 22.9 (C-4’) , 22.9 
(C-5’), 20.0 (C-26), 19.4 (C-27), 15.0 (C-25)   LR ESIMS (+) m/z 599.4 [M+1]+, HR 
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ESIMS (+) m/z 599.4678 [M+H]+ (C33H62N2O7 requires 599.4630), m/z 621.4463 
[M+Na]+  (C33H62N2O7Na requires 621.4449), see Appendices B-75 and C-2. 
   
6.5.2 Preparation of 108, 109, and 110.  Palmerolide A was dissolved and transferred 
into a round bottom flask and concentrated in vacuo. One granule of DMAP and a 
magnetic stir bar was added to the reaction flask before placing it under nitrogen. Dry 
dichloromethane was added followed by five equivalents of both Hunig’s base and 4-
bromo-benzoyl chloride. The reaction was allowed to stir overnight at rt before being 
quenched with methanol. The crude reaction mixture was separated on a reverse phase 
C18 analytical HPLC column equilibrated with 30% H2O:MeOH and run with 100% 
MeOH. 
Compound 108: white solid, [α]D22.7= -24.3 (c = 0.2, CDCl3);  UV/Vis (MeOH): λmax= 
248 (634). 1H NMR (500 MHz, d6-DMSO) δ 9.86 (1H, d, 10.4, 24-NH), 7.88 (2H, d, 8.5, 
Bz), 7.75 (2H, d, 8.5, Bz), 6.87 (1H, dd, 10.1, 14.2, H-24), 6.76 (1H, ddd, 5, 10, 15, H-3), 
6.54 (2H, br, OCONH2), 6.09 (1H, dd, 11.1, 14.6, H-15), 5.86 (1H, d, 14.2, H-23), 5.85 
(1H, m, H-8), 5.82 (1H, d, 15, H-2), 5.71 (1H, br, s, H-2’), 5.70 (1H, m, H-9), 5.6 (1H, d, 
11, H-16), 5.45 (1H, ddd, 4.5, 10.2, 14.7, H-14), 5.35 (1H, m, 10-OH), 5.35 (1H, m, H-7), 
5.15 (1H, d, 9.7, H-21), 4.86 (1H, m, H-19), 4.53 (1H, m, 5, 10.5, H-11), 4.21 (1H, m, H-
10), 2.70 (1H, qdd, 6.5, 7.5, 9.7, H-20), 2.17 (2H, m, H-4), 2.16 (1H, m, H-18a), 2.13 
(3H, s, H3-5’), 2.00 (1H, m, H-18b), 1.99 (2H, m, H2-13), 1.84 (3H, s, H3-4’), 1.74 (1H, 
m, H-6a), 1.72 (3H, s, H3-25), 1.65 (1H, m, H-6b), 1.64 (3H, s, H3-27), 1.64 (1H, m, H-
12a), 1.41 (1H, m, H-5a), 1.17 (1H, m, H-5b), 0.95 (1H, m, H-12b), 0.91 (3H, d, 6.6, H3-
26); 13C NMR (125 MHz, d6-DMSO) δ 165.3 (C-1), 164.1 (OC(O)pBzBr), 163.1 (C-1’), 
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156.5 (C(O)NH2), 151.8 (C-3’), 148.9 (C-3), 134.9 (C1-pBz), 132.6 (C-22), 131.9 (C-14), 
131.9 (C2-pBz), 131.9 (C6-pBz), 131.7 (C-17), 131.1 (C3-pBz), 131.1 (C5-pBz) 130.2 (C-
21), 129.8 (C4-Br), 129.7 (C-16), 128.2 (C-8), 127.8 (C-9), 126.7 (C-15), 122.2 (C-24), 
120.1 (C-2), 118.1 (C-2’), 116.4 (C-23), 76.5 (C-7), 74.7 (C-11), 73.8 (C-19), 68.9 (C-
10), 44.5 (C-18), 40.4 (C-6), 36.8 (C-20), 31.9 (C-4), 29.4 (C-12), 29.4 (C-13), 27.0 (C-
4’), 24.5 (C-5), 19.6 (C-5’), 17.1 (C-26), 16.2 (C-27), 12.7 (C-25); LR ESIMS (+) m/z 
767.2 [M + 1], HR ESIMS (+) m/z 767.2921 [M+H]+ (C40H51 BrN2O8 requires 767.2902), 
see Appendices B-80 and C-3. 
Compound 109: white solid, [α]D22.7= -23.6 (c = 0.3, CDCl3);  UV/Vis (MeOH): λmax= 
253 (609). 1H NMR (500 MHz, d6-DMSO) δ 9.86 (1H, d, 10.4, 24-NH), 7.92 (2H, d, 8.5, 
Bz), 7.78 (2H, d, 8.5, Bz), 6.87 (1H, dd, 10.5, 14.5, H-24), 6.76 (1H, ddd, 5.4, 9.5, 15.2, 
H-3), 6.56 (2H, br, OCONH2), 6.15 (1H, dd, 10.8, 14.9, H-15), 5.87 (1H, d, 14.5, H-23), 
5.81 (1H, d, 15.7, H-2), 5.71 (1H, br, s, H-2’), 5.65 (1H, m, H-8), 5.65 (1H, m, H-9), 5.63 
(1H, m, H-16), 5.48 (1H, m, H-14), 5.47 (1H, m, 4.4, 7.4, H-10), 5.16 (1H, d, 9.8, H-21), 
4.87 (1H, m, H-11), 4.81 (1H, m, 4.7, H-19), 4.81(1H, m, 7-OH), 3.94 (1H, ddd, 5.4, H-
7), 2.70 (1H, qdd, 6.5, 7.5, 9.7, H-20), 2.17 (2H, m, H2-4), 2.21 (1H, m, H-18a), 2.11 
(3H, s, H3-5’), 2.06 (2H, m, H2-13), 2.05 (1H, m, H-18b), 1.83(3H, s, H3-4’), 1.71 (3H, s, 
H3-25), 1.63 (3H, s, H3-27), 1.59 (1H, m, H-12a), 1.45 (1H, m, H-6a), 1.43 (1H, m, H-
12b), 1.39 (1H, m, H-5a), 1.36 (1H, m, H-6b), 1.18 (1H, m, H-5b), 0.90 (3H, d, 6.7, H-
26); 13C NMR (125 MHz, d6-DMSO) δ 165.8 (C-1), 164.3 (OC(O)pBzBr), 163.6 (C-1’), 
156.8 (C(O)NH2), 152.3 (C-3’), 149.7 (C-3), 137.8 (C1-pBz), 133.1 (C-22), 132.4 (C2-
pBz), 132.4 (C6-pBz), 131.7 (C3-pBz), 131.7 (C5-pBz), 131.6 (C-14),130.3 (C-17), 130.1 
(C-21), 129.7 (C-9), 127.4 (C4-Br), 123.9 (C-16), 128.1 (C-8), 127.6 (C-15), 122.6 (C-
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24), 121.4 (C-2), 118.6(C-2’), 116.8 (C-23), 74.9 (C-10), 74.2 (C-11), 72.3 (C-19), 71.1 
(C-7), 43.5 (C-18), 37.4 (C-6), 37.2 (C-20), 32.5 (C-4), 30.7 (C-12), 29.4 (C-13), 27.6 (C-
4’), 24.4 (C-5), 19.9 (C-5’), 17.4 (C-26), 16.6 (C-27), 13.1 (C-25); LR ESIMS (+) m/z 
767.2 [M + 1], HR ESIMS (+) m/z 767.2921 [M+H]+ (C40H51 BrN2O8 requires 767.2902), 
see Appendices B-85 and C-3. 
Compound 110: white solid, [α]D30= -47 (c = 0.5, CDCl3);  UV/Vis (MeOH): λmax= 212 
(1896), 348 (152). 1H NMR (500 MHz, d6-DMSO) δ 9.85 (1H, d, 10.7, 24-NH), 7.90 
(2H, d, 8.8, Bz), 7.84 (2H, d, 8.3, Bz), 7.75 (2H, d, 8.8, Bz), 7.71 (2H, d, 8.3, Bz), 6.87 
(1H, dd, 10.3, 14.7, H-24), 6.78 (1H, ddd, 5, 10, 15, H-3), 6.57 (2H, br, OCONH2), 6.16 
(1H, dd, 11.2, 14.7, H-15), 5.95 (1H, d, 4.9, H-9), 5.85 (1H, d, H-23), 5.83 (1H, m, H-2), 
5.81 (1H, d, H-8), 5.70 (1H, br, s, H-2’), 5.65 (1H, m, H-8), 5.63 (1H, m, H-16), 5.52 
(1H, m, H-14), 5.52 (1H, m, H-10), 5.43 (1H, m, H-7), 5.16 (1H, d, 9.8, H-21), 4.88 (1H, 
m, H-19), 4.87 (1H, m, H-11), 2.71 (1H, qdd, 6.5, 7.5, 9.7, H-20), 2.17 (2H, m, H2-4), 
2.21 (1H, m, H-18a), 2.11 (3H, s, H3-5’), 2.06 (2H, m, H2-13), 2.05 (1H, m, H-18b), 
1.83(3H, s, H3-4’), 1.72 (1H, m, H-6a), 1.71 (3H, s, H3-25), 1.66 (1H, m, H-6b), 1.63 
(3H, s, H3-27), 1.62 (1H, m, H-12a), , 1.43 (1H, m, H-12b), 1.39 (1H, m, H-5a), 1.18 
(1H, m, H-5b), 0.90 (3H, d, 6.7, H3-26); 13C NMR (125 MHz, d6-DMSO) δ 166.0 (C-1), 
164.3 (OCA(O)pBzBr), 164.3 (OCB(O)pBzBr), 163.6 (C-1’), 157.1 (C(O)NH2), 152.6 (C-
3’), 149.9 (C-3), 137.8 (CA1-pBz), 134.9 (CB1-pBz), 133.1 (C-22), 132.7 (CA2-pBz), 132.7 
(CA6-pBz), 132.7 (CB2-pBz), 132.7 (CB6-pBz),  131.7 (CA3-pBz), 131.7 (CA5-pBz), 131.7 
(CB3-pBz), 131.7 (CB5-pBz),131.6 (C-14),130.3 (C-17), 130.1 (C-21), 129.8 (CA4-pBz), 
127.4 (CB4-Br), 123.9 (C-16), 128.1 (C-9), 127.8 (C-8), 127.6 (C-15), 122.6 (C-24), 
121.4 (C-2), 118.6(C-2’), 116.8 (C-23), 74.9 (C-10), 74.2 (C-11), 72.3 (C-19), 71.1 (C-7), 
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43.5 (C-18), 37.4 (C-6), 37.2 (C-20), 32.5 (C-4), 30.7 (C-12), 29.4 (C-13), 27.6 (C-4’), 
24.4 (C-5), 19.9 (C-5’), 17.4 (C-26), 16.6 (C-27), 13.1 (C-25);   LR ESIMS (+) m/z 971.2 
[M + Na], m/z 967.3 [M+ NH3], HR ESIMS (+) m/z 949.2257[M+H]+ (C47H54Br2N2O9 
requires 949.2269) , see Appendices B-90 and C-4.   
 
6.5.3 Preparation of Compounds 111and 112.  Palmerolide A was dissolved and 
transferred into a round bottom flask and concentrated in vacuo. The flask was placed 
under nitrogen and approximately 1.1 eq of NaOMe dissolved in dry MeOH was added. 
The reaction was allowed to stir for 3 hr at room temperature before being quenched with 
wet MeOH. The crude reaction mixture was separated on a reverse phase C18 analytical 
HPLC column equilibrated with 30% H2O:MeOH and run with 100% MeOH. 
Compound 111: [α]D30= -27 (c = 0.3, CDCl3) , UV/Vis (MeOH): λmax = 211 (2164). 1H 
NMR (500 MHz, d6-DMSO) δ 9.86 (1H, d, 10.5, 24-NH),  6.86 (1H, dd, 10.1, 14.2, H-
24), 6.76 (1H, ddd, 5, 10, 15, H-3), 6.06 (1H, dd, 11.1, 14.6, H-15), 5.86 (1H, d, 14.2, H-
23), 5.76 (1H, d, 15, H-2), 5.70 (1H, br, s, H-2’), 5.61 (1H, d, 11, H-16), 5.57 (1H, m, H-
9), 5.49 (1H, m, H-8), 5.43 (1H, ddd, 4.5, 10.2, 14.7, H-14), 5.35 (1H, m, H-7), 5.15 (1H, 
d, 9.7, H-21), 4.86 (1H, m, H-19), 3.97 (1H, m, H-10), 3.83 (1H, m, H-7), 3.32 (1H, m, 
H-11), 2.70 (1H, qdd, 6.5, 7.5, 9.7, H-20), 2.17 (2H, m, H2-4), 2.18 (1H, m, H-18a), 2.13 
(3H, s, H3-5’), 2.00 (1H, m, H-18b), 1.91 (2H, m, H2-13), 1.84 (3H, s, H3-4’), 1.74 (1H, 
m, H-6a), 1.72 (3H, s, H3-25), 1.65 (1H, m, H-6b), 1.64 (3H, s, H3-27), 1.64 (1H, m, H-
12a), 1.41 (1H, m, H-5a), 1.17 (1H, m, H-5b), 0.95 (1H, m, H-12b), 0.91 (3H, d, 6.6, H3-
26); 13C NMR (125 MHz, d6-DMSO) δ 165.3 (C-1), 163.1 (C-1’), 151.8 (C-3’), 148.9 (C-
3), 132.6 (C-22), 131.9 (C-14), 131.7 (C-17), 130.2 (C-21), 129.8 (C-Br), 129.7 (C-16), 
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127.8 (C-9), 126.7 (C-15), 122.2 (C-24), 120.1 (C-2), 118.1 (C-2’), 116.4 (C-23), 74.4 
(C-19), 74.3 (C-11), 73.4 (C-10), 73.1 (C-7), 44.5 (C-18), 40.4 (C-6), 36.8 (C-20), 31.9 
(C-4), 29.4 (C-12), 29.4 (C-13), 27.0 (C-4’), 24.5 (C-5), 19.6 (C-5’), 17.1 (C-26), 16.2 
(C-27), 12.7 (C-25);  LR ESIMS (+) m/z 542.4 [M+1], m/z 564.3 [M+ Na], HR ESIMS 
(+) m/z 542.34600 [M+H]+ HR ESIMS (+) m/z 767.2921 [M+H]+ (C32H47NO6  requires 
542.3476), m/z  564.3293 [M+Na]+ (C32H47NO6Na  requires 564.3296), see Appendices 
B-95 and C-5. 
Compound 112: [α]D30= -24 (c = 0.5, CDCl3); UV/Vis (MeOH): λmax = 211 (1546). 1H 
NMR (500 MHz, d6-DMSO) δ 9.86 (1H, d, 10.5, 24-NH),  6.86 (1H, dd, 10.1, 14.2, H-
24), 6.11 (1H, dd, 11.1, 14.6, H-15), 5.86 (1H, d, 14.2, H-23), 5.80 (1H, m, H-9), 5.71 
(1H, br, s, H-2’), 5.66 (1H, d, 11, H-16), 5.55 (1H, ddd, H-14), 5.51 (1H, m, H-8), 5.15 
(1H, d, 9.7, H-21), 4.82 (1H, m, H-19), 4.25 (1H, m, H-7), 3.71 (1H, m, H-10), 3.70 (1H, 
m, H-3), 3.24 (1H, m, H-11), 2.70 (1H, qdd, 6.5, 7.5, 9.7, H-20), 2.45 (1H, dd, H-2a), 
2.23 (1H, m, H-2b), 2.18 (1H, m, H-18a), 2.13 (3H, s, H3-5’), 2.00 (1H, m, H-18b), 1.91 
(2H, m, H2-13), 1.84 (3H, s, H3-4’), 1.81 (H-4a), 1.65 (1H, m, H-6a), 1.72 (3H, s, H3-25), 
1.64 (3H, s, H3-27), 1.64 (1H, m, H-12a), 1.57 (1H, m, H-5), 1.49 (1H, m, H-6b), 1.15 
(1H, m, H-4b), 0.95 (1H, m, H-12b), 0.91 (3H, d, 6.6, H3-26); 13C NMR (125 MHz, d6-
DMSO) δ 170.4 (C-1), 163.6 (C-1’), 152.1 (C-3’), 134.8 (H-8), 133.6 (C-22), 132.0 (C-
17),131.9 (C-9), 131.4 (C-14), 130.5 (C-21), 128.0 (C-16), 127.3 (C-15), 122.8 (C-24), 
118.9 (C-2’), 117.1 (C-23), 75.5 (C-3), 75.0 (C-19), 73.6 (C-11), 72.2 (C-7), 66.9 (C-10), 
44.5 (C-18), 40.4 (C-2), 36.8 (C-20), 34.0 (C-12), 31.4 (C-4), 29.4 (C-13), 28.7 (C-6), 
27.0 (C-4’), 19.6 (C-5’), 18.8 (C-5), 17.7 (C-26), 16.2 (C-27), 12.8 (C-25); LR ESIMS 
(+) m/z 542.3 [M+1], m/z 564.3 [M+ Na], HR ESIMS (+) m/z 542.3468 [M+H]+ 
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(C32H47NO6  requires 542.3476), m/z 564.3283 [M+Na]+ (C32H47NO6Na requires 
564.3296), see Appendices B-100 and C-6. 
 
6.7 Cytotoxicity assay.   
 All tissue culture components were purchased from Fisher Scientific. The 
UACC-62 human melanoma cell line was provided by the National Cancer Institute 
(NCI), Division of Cancer Treatment and Diagnosis (DCTD). The cancer cells were 
cultured in RPMI supplemented with 10% fetal bovine serum, 2 mM glutamine, and 50 
μg/ml gentamicin. The cytotoxicity of the compounds were determined using the 
sulphorhodamine B (SRB) assay. A 96-well plate was inoculated with 100 µL of cell 
suspension in each well at a plating density of 5,000 cells/well. The plate was incubated 
at 37°C with 5% CO2, 95% air and 100% relative humidity for 24 hours prior to addition 
of experimental drugs.  The cells were dosed by adding 100 µL of media containing 5 
different drug concentrations (10 µM, 1 µM, 0.1 µM, 0.01 µM, 0.001 µM) of the 
compounds to be tested to the respective wells in triplicate. The assay plate was 
incubated for 48 hours following drug addition at 37°C with 5% CO2, 95% air and 100% 
relative humidity. The plate was removed from the incubator and the media aspirated 
from the wells. The cells were fixed using 50 µL of 10% cold trichloroacetic acid and 
kept at 4°C for 1 hour, subsequently being washed five times with distilled water. The 
plates were air-dried at room temperature and the cells stained with 100 µL of SRB 
solution (0.4% w/v SRB in 1% v/v acetic acid) for 10 minutes. The plate was washed five 
times with 1% acetic acid to remove excess SRB present in the wells and allowed to air 
dry. Protein bound stain was solubilized with 200 µL of tris base and mixed. The 
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absorbance was measured at 515 nm using a BioTek Synergy 2 microtitre plate reader 
and the IC50 values determined by plotting the optical density of SRB against the drug 
concentration for each well using the program Table Curve 2D v5.01. 
 
6.8 Leishmania Assay 
 Using a Beckman Coulter Biomek 3000 automated sampler, 120 µL of Hank’s 
Buffered Salt Solution (HBSS) was added to each well of a 96-well plate.  Mother plates 
were made by adding 5μ L of crude extracts that had been suspended in DMSO at a 
concentration of 60 mg/mL to the first column of the 96-well plate. Serial dilutions were 
made across the plate resulting in twelve concentrations ranging from μgÆng/mL.  The 
wells of the mother plate were aspirated to ensure a homogenous mixture of the samples 
then 10 µL was transferred from each well into a daughter plate. The Leishmania 
parasites were added to each well (90 µL) of the daughter plate and plate incubated for 3 
days at 37°C. After 3 days approximately 20 µL of (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) is added to each well 
and the plate incubated for 4 hr at 37°C. The MTS reacted with a dehydrogenase enzyme 
in the live parasite and was reduced to a colored formazan product which was quantified 
by reading the plate at 490 nm. The amount of formazan detected was directly 
proportional to the number of living parasites. 
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Appendix A: NMR Data Tables 
 
 
A-1 1H and 13C NMR Spectral Data for Palmerolides D (98) and E (99)a 
 
 Palmerolide D   Palmerolide E 
Positionb δH  δC  HMBC δH  δC HMBC 
 1   165.5   165.2 
 2  5.76 (d, 15.8) 120.6   1,4 5.77(d, 15.7)  120.3 1, 4 
 3  6.71 (ddd, 4, 11.5, 15.7) 149.4   1,2,5 6.74 (ddd, 4.3, 11.5, 15.7) 149.7 1, 4,5 
 4 a 2.14 (m) 32.4   2, 3,5 2.15 (m)  32.3 2,3,5 
  b 2.11 (m)    2.00 (m)  2,3 
 5 a 1.31 (m) 24.2  1.31 (m)  25.0   
  b 1.05 (m)   1.07 (m) 
 6 a 1.51 (ddd, 4.4, 7.7, 11.2 )37.8  1.50 (ddd, 4.4)  37.8 4,5,7,8 
  b 1.33 (m)    1.30 (m)     5,7,8 
 7  3.82 (ddd, 4.4, 6.5, 7.9) 72.6  3.83 (ddd, 4.4, 6.8, 8.2) 72.5 9 
 8  5.53 (dd, 7.9, 15.3) 133.6 7, 9,10 5.54 (dd, 8.2, 15.4) 133.6 7,9,10 
 9  5.49 (dd, 2.9, 15.3) 129.0 7,8,11,10 5.49 (dd, 2.9, 15.4) 128.9 8,7,10 
 10  4.15 (s) 69.4 11 4.13 (br s)  69.2            8-13 
 11  4.48 (ddd, 1.9, 5, 10.6) 75.2 9,10,12,13,1” 4.47 (ddd, 1.5, 5.1, 10.7) 75.1 9-13,1” 
 12 a 1.60 (m) 29.5  1.61  29.4 13 
  b 1.01 (m)   1.05 (m)  13 
 13  1.94 (m) 29.5  1.97 (m)  29.4           12,14,15 
 14  5.41 (ddd, 5, 10, 14.6) 132.7 13,16 5.43 (ddd, 5.2, 9.8, 14.8) 132.2         12/13,16 
 15  6.04 (dd, 11.6, 14.6) 126.4  6.05 (dd, 10.7, 14.8) 126.3         13,14,16 
 16  5.59 (d, 11.6) 127.8 14,15,17,18,25 5.61(d, 10.7)  128.0         14-18,25 
 17   131.7   131.1 
 18 a 2.16 (dd, 1.4, 12.8) 43.3 16,17,25 2.16 (dd, 1.4, 12.4) 43.0            16,17,25 
  b 2.00 (dd, 11, 12.8)   16,17,19,25 2.07 (dd, 11, 12.4)                    16,17,19,25 
 19  4.84 (ddd, 1.4, 7.7, 11) 73.9 1,26 5.02 (ddd, 1.4, 7.5, 11)       72.6     1,17,20,21,26 
 20  2.68 (qdd, 6.9, 7.7, 9.7) 36.7 19,21 2.64 (qdd, 6.8, 7.5, 9.3) 38.1       19,21,22,26 
 21  5.14 (d, 9.7) 130.2 19,26,27 6.55 (dd, 1.5, 9.3)  154.9 19,20,23,25,27 
 22   132.0     138.7 
 23  5.86 (d, 14.6) 117.0 21,24,27 9.40 (s)  195.6          21,22,27 
 24  6.85 (dd, 10.4, 14.6) 122.2 22 
 25  1.60 (s) 16.3 16,17,18 1.63 (s)  16.1            16,17,18 
 26  0.89 (d, 6.7) 17.2 19,20,21 1.01 (d, 6.8)  15.5            19,20,21 
 27  1.70 (s) 12.8 21,22,23 1.68 (s)  9.2              21,22,23 
 1’   162.9  
 2’  5.81 (s) 119.7 1’,4’,8’ 
 3’   152.7 
 4’  3.34(s) 40.3 2’,3’,5’ 
 5’   143.0 
 6’  4.72 (s) 111.9 4’,7’ 
 7’  1.61 (s) 22.0 4’,5’,6’ 
 8’  1.76 (s) 25.1 2’,3’,4’  
 1”    156.8     156.7 
 1”-NH2 6.45 (br)    6.48 (br) 
 7-OH 4.53 (d, 3.8)    4.70 (d, 4.1) 
 10-OH 5.19 (m, 4.5)    5.18 (d, 4.9)  
 24-NH 9.94 (d, 10.3)   1’ 
 
a500 MHz for 1H, 125 MHz for 13C, DMSO-d6.   
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Appendix A (continued) 
 
 
A-2 1H and 13C NMR Spectral Data for Palmerolides F (100) and G (101)a 
 
 Palmerolide F   Palmerolide G 
Positionb δH             δC      HMBC δH δC        HMBC 
 1 165.3 165.5 
 2 5.77 (1H, d, 16.0) 120.5 1,4 5.76 (d, 15.4)  120.5 1,4 
 3 6.71 (1H, ddd, 4.8, 10.3, 16.0)149.2 1,2,4,5 6.71 (ddd, 4.8, 10, 15.4) 149.4 1,2,4,5 
 4 a 2.11 (1H, m)   32.3 2,3,5,6 2.10 (m)    32.6 3,5 
 b 1.84 (m)  1.84 (m) 
 5 a 1.31 (1H, m)   24.9 6,7 1.28 (m)    25.1 
 b 0.98 (1H, m)   7 1.06 (m) 
 6 a 1.48 (1H, m)   37.7 5,7,8 1.49 (ddd,4.4,7.7, 11)   38.6 5,7,8,9 
 b 1.30 (1H, m)   5,7,8 1.31   4,7,8 
 7 3.83(1H, d, 4.0)   72.5 6,9 3.83(ddd, 4.4, 6.5, 7.9) 73.4 
 8 5.55 (1H, dd, 7.8, 15.9) 133.5 6,7,9,10 5.54 (dd, 7.9, 14.8) 134.5 7,10 
 9 5.48 (1H, dd, 2.3, 15.8) 128.8 8 5.46 (dd, 2.2, 14.8) 129.7 7,10 
 10 4.14 (1H, br s)   69.1 9,12/13 4.13 (s)    70.2 11 
 11 4.48 (1H dd, 4.6, 11.2)   75.0 9,10,12/13,1” 4.48 (ddd, 1.5, 4.9, 10.8)   76.1   9-12,1” 
 12 a 1.60 (1H, m)   29.3 11,12/13 1.13    30.1     10,13 
 b 0.97 (1H, m)   12/13,14 0.98 (m) 
 13 1.94 (2H, m)   29.3 12/13,14,15 1.98(m)    30.1     14,15 
 14 5.41 (1H, ddd, 4.2, 10.4, 15.0)131.9 12/13,16 5.41 (ddd, 4.4,10.1,14.8) 132.9     13-16 
 15 6.05 (1H, dd, 11.2, 15.0) 126.3 16,17,12/13 6.03 (dd, 11.1, 14.8) 127.3     13-16 
 16 5.59 (1H, d, 10.6) 127.7 14,15,18,25 5.58 (d, 11.1)  128.6     16,18 
 17 131.5   132.5 
 18 a 2.15 (1H, m, 1.7)   43.2 16,17,25 2.16 (dd, 1.5, 13.2)   37.1     16-19 
 b 1.99 (1H, q, 12)   16,17,19,20,25 1.98 (dd, 12, 13.2)                                16,17 
 19 4.84 (1H, 1.7, 7.9, 12)   73.7 1,17,21,26 4.82 (ddd, 1.5, 8, 12)             74.5    17,18,26 
 20 2.68 (qdd, 6.7,7.9,9.6)   36.5 18,19,21,22,26 2.65 (qdd, 6.6, 8, 10)     40.3    19,21,22,25 
 21 5.14 (1H, d, 9.6) 130.1 19,20,23,26,27 5.01(d, 10)  129.3     18,23 
 22 132.3 132.1 
 23 5.87 (1H, d, 15.0) 116.9 21,22,24,27 6.19(d,14.3)  109.8     21,24 
 24 6.77 (1H, dd, 10.3, 15.0) 121.8 22,23,1’ 6.93(dd, 10.4,14.3)               125.4    21,22,23 
 25 1.61 (3H, s)   16.1 16,17,18 1.60 (s)    17.1      14,16 
 26 0.90 (3H, d, 7.6)   17.0 19,21,20 0.89 (d, 6.6)                          18.2      19,20,21 
 27 1.70 (3H, s)   12.6 21,22,23 1.76 (s)  21.1         21,22,23 
 1’ 167.4 164.1 
 2’  2.91 (1H, s)   44.5 1’,3’,4’,5’ 5.68                             118.7    1’,4’,5’,27 
 3’  139.8 153.6 
 4’ a 4.82 (1H, br s ) 113.5 2’,5’  2.12    20.1 1’-5’ 
  b 4.79 (1H, br s)   2’,3’,5’ 
 5’   1.71 (3H, s)   22.2 1’,2’,3’,4’ 1.84                                       28.0         2’,3’,4’ 
 7-OH   4.69 (1H, br s)   4.73 (d,4.4) 
 10-OH 5.17 (1H, d, 3.8)  9 5.20 (d, 4,7) 
 24-NH 9.93 (1H, d, 10.3) 23,24,1’ 9.97 (d,10.2) 1’ 
OCONH2 6.48 (2H, br) 156.6  6.48 (s)  157.6 
 
a500 MHz for 1H, 125 MHz for 13C, DMSO-d6.   
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Appendix A (continued) 
 
 
A-3 1H and 13C NMR Spectral Data for Palmerolides B (96) and H (102) a 
 
  Palmerolide B     Palmerolide H 
Positionb  δH   δC HMBC  δH   δC             HMBC 
1 168.2   168.2 
2 5.70 (1H, d, 15)    122.3    1,4  5.70 (d, 15.5)  122.3      3,4 
3 6.74 (1H, ddd, 4, 11, 15) 150.7  1,4,5  6.75 (ddd, 4, 11.5, 15.5) 150.7       1,2,4 
4   a 2.14 (1H, m)  34.0    2.14 (1H, m)    33.9   2,3  
     b 2.10 (1H, m)  2.10 (1H, m)                                       2,3,5 
5   a 1.34 (1H, m)                           26.1   1.32 (1H, m)   26.1         3,4 
     b 1.14 (1H, m)     1.10 (1H, m)                                      3,6 
6   a 1.55 (1H, m)                           31.8   1.56 (1H, m)   31.8       6,8,9 
     b 1.08 (1H, m)     1.10 (1H, m)   
7 4.57 (1H, m)                           77.4 6,8, OCONH2 4.58(1H, m)  77.5         7,9,10 
8 4.20 (1H, m)                           72.1 9  4.20 (1H, m)                    72.2         7,11,12  
9  5.72 (1H, m)                           133.4  8, 10  5.74 (1H, m)  132.3       8,12 
10 5.64 (1H, m)                           131.0 8, 11  5.63 (1H, m)                   131.1       9,10,13,  
                                                         OCONH2 
11 4.64 (1H, m)                            81.6   4.66 (1H, m)                   81.9          9-12,1” 
12  a 1.79 (1H, m)                            36.6 11  1.80 (1H, m)    36.6        13,15,16 
      b 1.53 (1H, m)  11   1.55 (1H, m) 
13  a 1.96 (1H, m)                            30.9   1.96(1H, m)    30.8        14,15,25 
      b         1.21 (1H, m)                1.21 (1H,m)                  14,16  
14 5.38 (1H, ddd, 4, 10.5, 14.5)   133.3 15  5.38 (1H, m)  133.4      5,16,18,25 
15 6.01 (1H, dd, 10.5, 14.5)   128.0 14,17  6.02 (1H, dd, 10, 14.5) 128.1      16,19,25 
16 5.57 (1H, d, 10.9)    129.8 15,18  5.57(1H, d, 11.5)  128.1      16,18 
17      132.8      133.0 
18  a 2.15 (1H, m)    45.2   2.15 (1H, m)    45.2      9,20,26,27 
      b 1.99 (1H, m)    45.2 20  2.00 (1H, m)                              18,19,21,26 
19 4.82 (1H, m)    76.6 1,20  4.84 (1H, m)                        76.2         21,23,27 
20 2.68 (qdd, 5,10,10)    38.7   2.68                                    38.7         21,24,27 
21 5.08 (1H, d, 10)    132.2 19,20,22,25 5.09(1H, d, 10)                    132.3      22,23,1’ 
22       134.5                                                                                  134.5       15,16,18 
23 5.85 (1H, d, 15)    119.6 21,22,24,25 5.87(1H, d, 14.6)                 119.7     22,24,25 
24 6.86 (1H, dd, 15)    122.7 22,23,1’  6.87(1H, d, 14.6)                 122.8      22,23,1’ 
25 1.58 (3H, s)    16.7 16,17,18  1.59 (3H, s)                          13.2        16,18 
26 0.88 (3H, d, 6.5)    17.7 19,21,20  0.89 (3H, d, 6.7)                   17.7       19,20,21 
27 1.71 (3H, s)    13.2 21,22,23  1.72 (3H, s)                          16.6        22,23 
1’      166.7                                                                                  166.0 
2’ 5.64 (1H, br s)    118.9 1’,3’,4’,5’ 5.76 (1H, s)  120.5  
3’      154.9   155.7     1’,4’,8’ 
4’ 1.81 (3H, s)   27.7 1’,2’,3’,5’   3.44 (2H, s)    42.1  
5’        2.09 (3H, s)   20.4 1’,2’,3’,4’       144.6  2’-7’ 
6’        4.69 (2H, s)  112.6 
7’        1.61 (3H, s)  22.4  4’,8’  
 8’ 1.76 (3H, s)   24.8        4’,5’,6’ 
OCONH2                                               159.8            159.9       2’,3’,4’  
 
a500 MHz for 1H, 125 MHz for 13C, CD3OD.   
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Appendix A (continued) 
 
 
A-4 1H and 13C NMR Spectral Data for Palmerolides C (97) and K (104) a 
 
 Palmerolide C   Palmerolide K 
Positionb       δH  δC    HMBC        δH      δC           HMBC 
 1 166.9   64.5 
 2 5.73 (1H, d, 15.5) 122.0   1,4  5.75 (1H,d, 14.7) 120.7  1,4 
 3 6.77 (1H, ddd, 7.4, 7.5, 15.5) 149.8   1,2,4,5 6.81 (1H, ddd,7.4, 7.5,14.7)   149.4  1,4,5 
 4 a 2.11(1H, m)   31.7   2,6  2.15 (1H, m)    30.7  2,3,5 
 b 2.06 (1H, m)                                                 2,3,5,6                2.13 (1H, m)    2,3,5 
 5 a 1.93 (1H, m)   32.2   6,7  1.37 (1H, m)    27.9           3,4,6,7 
 b 1.84 (1H, m)    3,7   1.34 (1H, m)    3 
 6  5.54 (1H, m)  131.8   5,7  5.55 (1H, m)  130.6  2,7,8 
 7 5.58(1H, d, 4.0)  131.1   6,8  5.55(1H, m)  130.6         2,6,8 
 8 3.96 (1H, dd, 7.8, 15.9) 72.8   6,7,9  3.97 (1H, dd, 7.8, 15.9) 72.0  6,7 
 9 3.56 (1H, m) 75.6   10  3.57 (1H, m)  74.8        6,7,10,11 
 10 4.56 (1H, ddd, 2.2,7.2,10.5)   74.2   11,OCONH2  4.56 (1H, m, 2.5,7,10.5)  73.4        9,11,12 
 11    a 1.49 (1H, m)   28.7   10,12  1.34 (1H, m)   29.8  12 
            b      1.30 (1H, m)                     10,12       1.30 (1H, m)                                        12 
 12  1.95 (1H, m)   30.1   10  1.54 (1H, m)    30.1          13,14  
 13 a 2.01 (1H, m)   30.1   15  1.97(1H, m)    31.2          12,14 
  b 1.89 (1H, m)                                                15                         1.92 (1H, m)                   12,14 
 14 5.46 (1H, ddd, 5, 10, 15)        132.3   13,15,16  5.48 (ddd, 5, 10, 15) 132.1   15 
 15 6.08 (1H, dd, 11.5, 15.0)     127.2   16,17,12/13  6.10 (1H,dd, 11.8, 14.7) 126.4        13 
 16 5.63 (1H, d, 11.5)     128.8   14,15,25  5.67 (!H,d, 11.8) 128.3       17,18,26 
 17     132.5   130.1 
 18 a 2.14 (1H, m,10.5)     44.1   16,17,19,20,25 2.18(dd)   42.9     16- 20,26 
 b 1.58 (1H, m,)      16,17,19,25  
 19 4.85 (1H, ddd,2.2,7.8,10.5)    74.7   1,17,18,20,21,26  5.04 (1H, q,6.7) 72.5      1,17,21,26 
 20 2.70 (1H,qdd, 6.7, 7.8,9.5)     37.4   16,19,21,22,26 2.98 (1H, m)    37.3        19-22,25 
 21 5.15 (1H, d, 9.5)    130.5   19,20,23,26,27 6.58(1H, d, 10.3) 154.5  20,23,24,25 
 22    133.3   138.4 
 23 5.85 (1H, d, 14.6)   117.2   21,22,24,27  9.41(1H, s)  194.9      22,24 
 24 6.85 (1H, dd, 9, 14.6)   122.8   22,23,1’  1.68(3H, s)  8.62         21,22,23 
 25 1.69 (3H, s)   13.3   16,17,18  1.03 (3H,d,6.7) 15.6        19,20,21 
 26 0.90 (3H, d, 7)   17.8   19,20,21  1.61(3H,s)  15.6        16,17,18 
 27 1.59 (3H, s)   16.5   21,22,23  
 1’   164.0  
 2’  5.68 (1H, s)   118.8   1’,3’,4’,5’  
 3’    152.5    
 4’  1.82 (3H, s)   27.4   1’,2’,3’,5’  
 5’  2.11 (3H, s)   20.3   1’,2’,3’,4’  
 8-OH 4.62 (1H, d, 5.12)     4.62 ( 1H, d, 5)                                   6,7,8,9 
 9-OH 4.72 (1H, d, 4.76)   9   4.72 (1H, d, 5)                    8,9,10 
 24-NH 9.85 (1H, d, 10)     23,24,1’   
OCONH2 6.37 (2H, br) 157.6  6.36 (2H, br) 156.7 
 
a500 MHz for 1H, 125 MHz for 13C, DMSO-d6 
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Appendix A (continued) 
 
 
A-5 1H and 13C NMR Spectral Data for glycosphingolipid 113a 
 
 Position δC (mult.) δH (mult., J [Hz]) 
1 a 
   b 
69.3 (CH2) 3.93 (dd, 10.5, 5.8) 
3.53 (dd, 10.5, 3.8 
2 53.5 (CH) 3.83 (m) 
2-NH -- 7.41 (d, 9.5) 
3 70.6 (CH) 3.99[a] 
3-OH -- 4.94 (m) 
4 131.1 (CH) 5.43 (d, 15.6, 6.7) 
5 130.0 (CH) 5.59[a] 
6 31.6 (CH2) 2.01(m) 
7 27.0 (CH2) 2.13 (m) 
8 129.2 (CH) 5.39 (t, 7.0) 
9 133.0 (C) -- 
10 135.4 (CH) 6.00 (d, 15.6) 
11 127.1 (CH) 5.51[a] 
12 32.0 (CH2) 2.02 (m) 
13 25.2 (CH2) 1.35[a] 
14 29.2 (CH2) 1.25[a] 
15 29.2 (CH2) 1.25[a] 
16 32.2 (CH2) 1.22[a] 
17 22.7 (CH2) 1.26[a] 
18 14.6 (CH3) 0.84 (t, 6.5) 
19 12.9 (CH3) 1.64 (s) 
1’ 104.2 (CH) 4.12 (d, 7.6) 
2’ 73.1 (CH) 2.96 (8.5, 3.8) 
2’-OH -- 4.97[a] 
3’ 77.9 (CH) 3.13 (dd, 9.0, 3.5) 
3’-OH -- 4.96[a] 
4’ 69.7 (CH)v 3.04 (dd, 9.0, 4.4) 
4’-OH -- 4.91(m) 
5’ 74.0 (CH) 3.14[a] 
6’ a 
     b 
61.6 (CH2) 3.66 (dd, 10, 5.9) 
3.41(dt, 11.7, 5.7) 
6’-OH -- 4.52 (t, 6.0) 
1” 175.7 (C=O) -- 
2” 71.6 (CH) 3.81 (m) 
2”-OH -- 4.00[a] 
3” a 
     b 
35.2 (CH2) 1.56 (m) 
1.41 (m) 
4”  25.4 (CH2) 1.29[a] 
6”-17” 29.5 (CH2) 1.24[a] 
18” 14.6 (CH3) 0.84 (t, 6.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
500 MHz for 1H, 125 MHz for 13C, DMSO-d6 
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Appendix A (continued) 
 
 
A-6 1H and 13C NMR Spectral Data for glycosphingolipids 114a-b 
 
 Position δC (mult.) δH 
1 a 
   b 
69.3 (CH2) 3.93 
3.53 
2 53.5 (CH) 3.83 
2-NH -- 7.41 
3 70.6 (CH) 3.99 
3-OH -- 4.94 
4 131.1 (CH) 5.43 
5 130.0 (CH) 5.59 
6Æy 29.0(CH2) 1.26 
y-terminus 14.6 (CH3) 0.84 
1’ 104.2 (CH) 4.12 
2’ 73.1 (CH) 2.96 
2’-OH -- 4.97 
3’ 77.9 (CH) 3.13 
3’-OH -- 4.96 
4’ 69.7 (CH)v 3.04 
4’-OH -- 4.91 
5’ 74.0 (CH) 3.14 
6’ a 
b 
61.6 (CH2) 3.66 
3.41 
6’-OH -- 4.52 
1” 175.7 (C=O) -- 
2” 71.6 (CH) 3.81 
2”-OH -- 4.00 
3” a 
b 
35.2 (CH2) 1.56 
1.41 
4” 25.4 (CH2) 1.29 
5”Æx 29.5 (CH2) 1.24 
x-terminus 14.6 (CH3) 0.84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
500 MHz for 1H, 125 MHz for 13C, DMSO-d6  
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Appendix B: Selected NMR Data 
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B-1 1H NMR Spectrum of Palmerolide D (98) in DMSO-d6, 500MHz 
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Appendix B (continued) 
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B-2 13C NMR Spectrum of Palmerolide D (98) in DMSO-d6, 500MHz 
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Appendix B (continued) 
 
 
 B-3 gCOSY of Palmerolide D (98) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-4 gHMBC of Palmerolide D (98) in DMSO-d6 , 500 MHz 
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Appendix B (continued) 
 
 
B-5 gHMQC of Palmerolide D (98) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-6 ROESY of Palmerolide D (98) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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Ch i l Shift ( )  
B-7 1H NMR spectrum of palmerolide D (+)-MTPA diester in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-8 1H NMR spectrum of palmerolide D (-)-MTPA diester in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-9 1H NMR Spectrum of Palmerolide E (99) in DMSO-d6, 500MHz  
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Appendix B (continued) 
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B-10 13C NMR Spectrum of Palmerolide E (99) in DMSO-d6, 500MHz 
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Appendix B (continued) 
 
 
 
B-11 gCOSY of Palmerolide E (99) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
 
B-12 gHMBC of Palmerolide E (99) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
  
B-13 gHMQC of Palmerolide E (99) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
 
B-14 ROESY of Palmerolide E (99) in DMSO-d6, 500MHz  
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Appendix B (continued) 
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Ch i l Shift ( )  
B-15 1H NMR spectrum of palmerolide E (+)-MTPA diester in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-16 1H NMR spectrum of palmerolide E (-)-MTPA diester in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-17 1H NMR Spectrum of Palmerolide F (100) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-18 13C NMR Spectrum of Palmerolide F (100) in DMSO-d6, 500MHz 
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Appendix B (continued) 
 
 
B-19 gCOSY of Palmerolide F (100) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-20 gHMBC of Palmerolide F (100) in DMSO-d6 , 500 MHz 
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Appendix B (continued) 
 
 
B-21 gHMQC of Palmerolide F (100) in DMSO-d6 , 500 MHz 
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Appendix B (continued) 
 
 
B-22 ROESY of Palmerolide F (100) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-23 1H NMR spectrum of palmerolide F (+)-MTPA diester 
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                                                          B-24 1H NMR spectrum of palmerolide F (-)-MTPA diester 
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Appendix B (continued) 
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B-25 1H NMR Spectrum of Palmerolide G (101) in DMSO-d6, 500MHz 
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Appendix B (continued) 
 
180 160 140 120 100 80 60 40 20 0 PPM
 
B-26 13C NMR Spectrum of Palmerolide G (101) in DMSO-d6, 500MHz 
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Appendix B (continued) 
 
 
B-27 gCOSY of Palmerolide G (101) in DMSO-d6, 500 MHz 
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B-28 gHMBC of Palmerolide G (101) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
B-29 gHSQC of Palmerolide G (101) in DMSO-d6, 500 MHz  
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Appendix B (continued) 
 
B-30 ROESY of Palmerolide G (101) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-31 1H NMR spectrum of palmerolide G (+)-MTPA diester 
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Appendix B (continued) 
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B-32 1H NMR spectrum of palmerolide G (-)-MTPA diester 
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Appendix B (continued) 
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B-33 1H NMR Spectrum of Palmerolide B (96) in CD3OD, 500 MHz  
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Appendix B (continued) 
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B-34 13C Spectrum of Palmerolide B (96) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
B-35 gCOSY of Palmerolide B (96) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
B-36 gHSQC of Palmerolide B (96) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
B-37  gHMBC of Palmerolide B (96) in CD3OD, 500 MHz 
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B-38 ROESY of Palmerolide B (96) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 
 
B-39 gHSQMBC of Palmerolide B (96) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 
B-40 gHSQMBC of Palmerolide B (96) in CD3OD, 500 MHz   
 2,3JC,H      H8-C6,7,9,10  
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Appendix B (continued) 
 
B-41 gHSQMBC of Palmerolide B (96) in CD3OD, 500 MHz   
 2,3JC,H      H7-C6,8 
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Appendix B (continued)  
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B-42 1H NMR Spectrum of Compound 103 in CD3OD, 500 MHz 
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B-43 13C NMR Spectrum of Compound 103 in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 
B-44 gCOSY of Compound 103 in CD3OD, 500 MHz 
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B-45 gHMBC of Compound 103 in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 B-46 gHMQC of Compound 103 in CD3OD, 500 MHz 
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B-47 1H NMR spectrum of (+)-MTPA monoester of Compound 103 
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B-48 1H NMR spectrum of (-)-MTPA monoester of Compound 103 
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B-49 1H NMR Spectrum of Palmerolide H (102) in CD3OD, 500 MHz 
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Appendix B (continued) 
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B-50 13C NMR Spectrum of Palmerolide H (102) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 
B-51 gCOSY of Palmerolide H in (102) CD3OD, 500 MHz 
 
176 
 
 
Appendix B (continued) 
 
 
B-52 gHSQC of Palmerolide H (102) in CD3OD, 500 MHz 
 
177 
 
 
Appendix B (continued) 
 
 
B-53  gHMBC Spectrum of Palmerolide H (102) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 
B-54 ROESY of Palmerolide H (102) in CD3OD, 500 MHz 
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Appendix B (continued) 
 
 
 B-55 gHSQMBC of Palmerolide H (102) in CD3OD, 500 MHz     
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Appendix B (continued) 
 
B-56 gHSQMBC of Palmerolide H (102) in CD3OD, 500 MHz 
 2,3JC,H      H8-C6,7,9,10  
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B-57 gHSQMBC of Palmerolide H (102) in CD3OD, 500 MHz 
 2JC,H      H7-C8  
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Appendix B (continued) 
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B-58 1H NMR Spectrum of Palmerolide C (97) in d6-DMSO, 500 MHz 
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Appendix B (continued) 
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B-59 13C NMR Spectrum of Palmerolide C (97) in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-60 gCOSY Spectrum of Palmerolide C (97) in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-61 gHSQC of Palmerolide C (97) in d6-DMSO, 500 MHz 
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B-62 gHMBC of Palmerolide C (97) in d6-DMSO, 500 MHz 
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B-63 ROESY of Palmerolide C (97) in d6-DMSO, 500 MHz 
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B-64 gHSQMBC of Palmerolide C (97) in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-65 gHSQMBC of Palmerolide C (97) in d6-DMSO, 500 MHz 
2,3 J C,H 
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Appendix B (continued) 
 
 
B-66 gHSQMBC of Palmerolide C (97) in d6-DMSO, 500 MHz 
 2,3 J C,H 
C11 (28.7 ppm)
H10 (4.56 ppm)
OCONH2 (156.7 ppm)
C8 (72.87 ppm)
C9 (74 55 )
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Appendix B (continued) 
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B-67 1H NMR spectrum of palmerolide C (+)-MTPA monoester 
H
H
O H
MTPA
H OH
H OR
6
7
8 9 10
5.70
5.79
5.53
3.92
4.58
190 
 
Appendix B (continued) 
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B-68 1H NMR spectrum of palmerolide C (-)-MTPA monoester 
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B-69 1H NMR Spectrum of Palmerolide K (104) in d6-DMSO, 500 MHz 
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Appendix B (continued) 
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B-70 13C Spectrum of Palmerolide K (104) in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-71 gCOSY of Palmerolide K (104) in d6-DMSO, 500 MHz  
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Appendix B (continued) 
 
 
B-72  gHSQC of Palmerolide K (104) in d6-DMSO, 500MHz 
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Appendix B (continued) 
 
 
B-73 gHMBC Spectrum of Palmerolide K (104) in d6-DMSO, 500 MHz 
 
196 
 
Appendix B (continued) 
 
 
B-74 ROESY of Palmerolide K (104) in d6-DMSO, 500 MHz  
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B-75 1H Spectrum of Palmerolide A Hydrogenation Product (107) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-76 13C Spectrum of Palmerolide A Hydrogenation Product (107) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
 
B-77 gCOSY of Palmerolide A Hydrogenation Product (107) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-78 gHMBC of Palmerolide A Hydrogenation Product (107) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-79 gHMQC of Palmerolide A Hydrogenation Product (107) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-80 1H NMR Spectrum of Palmerolide A C-7 p-bromobenzoate (108) in DMSO-d6, 500 MHz 
 
O
O
O NH2
O
HO
H
N
O
OR
7 R =
O
Br
203 
 
Appendix B (continued) 
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Ch i l Shift ( )  
B-81  13C Spectrum of Palmerolide A Palmerolide A C-7 p-bromobenzoate (108) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
B-82  gCOSY of Palmerolide A Palmerolide A C-7 p-bromobenzoate (108) in DMSO-d6, 500 MHz  
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Appendix B (continued) 
 
B-83 gHMBC of Palmerolide A C-7 p-bromobenzoate (108) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
B-84 gHMQC of Palmerolide A C-7 p-bromobenzoate (108) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
10 8 6 4 2 PPM 
B-85 1H NMR Spectrum of Palmerolide A C-10 p-bromobenzoate (109) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
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B-86 13C NMR Spectrum of Palmerolide A C-10 p-bromobenzoate (109) in DMSO-d6, 500 MHz. 
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Appendix B (continued) 
 
 
B-87 gCOSY of Palmerolide A C-10 p-bromobenzoate (109)  in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-88 gHMBC of Palmerolide A C-10 p-bromobenzoate (109) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
 
B-89 gHMQC of Palmerolide A C-10 p-bromobenzoate (109) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B-90 1H NMR Spectrum of Palmerolide A C-7/C-10 p-bromobenzoates (110) in DMSO-d6, 500 MHz 
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B-91 13C NMR Spectrum of Palmerolide A C-7/C-10 p-bromobenzoates (110) in DMSO-d6, 500 MHz 
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B-92 gCOSY of Palmerolide A C-7/C-10 p-bromobenzoates (110) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-93 gHMBC of Palmerolide A C-7/C-10 p-bromobenzoates (110) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-94 gHMQC of Palmerolide A C-7/C-10 p-bromobenzoates (110) in DMSO-d6, 500 MHz 
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10 8 6 4 2 PPM 
B-95 1H NMR Spectrum of Palmerolide C-11 alcohol (111) in DMSO-d6, 500MHz 
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B-96 13C NMR Spectrum of Palmerolide C-11 alcohol (111) in DMSO-d6, 500MHz 
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Appendix B (continued) 
 
 
B-97 gCOSY of Palmerolide C-11 alcohol (111) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-98     gHMBC of Palmerolide C-11 alcohol (111)in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-99 gHSQC of Palmerolide C-11 alcohol (111) in DMSO-d6, 500 MHz 
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B-100    1H NMR Spectrum of Palmerolide A C-3 alcohol (112) in DMSO-d6, 500MHz 
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B-101 13C NMR Spectrum of Palmerolide A C-3 alcohol (112) in DMSO-d6, 500MHz. 
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Appendix B (continued) 
 
 
B-102 gCOSY of Palmerolide A C-3 alcohol (112) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-103 gHMBC of Palmerolide A C-3 alcohol (112) in DMSO-d6, 500 MHz 
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Appendix B (continued) 
 
 
B-104 gHMQC of Palmerolide A C-3 alcohol (112) in DMSO-d6, 500 MHz 
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B-105 1H NMR Spectrum of glycosphingolipid 113a in d6-DMSO, 500 MHz 
C43H79NO9
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B-106 13C NMR Spectrum of glycosphingolipid 113a in d6-DMSO, 125 MHz 
229 
 
Appendix B (continued) 
 
 
  
B-107 gCOSY data of glycosphingolipid 113a in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
 
 B-108 gHMBC data of glycosphingolipid 113a in d6-DMSO, 500 MHz  
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Appendix B (continued) 
 
 
B-109 gHSQC data of glycosphingolipid 113a in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-110 ROESY data of glycosphingolipid 113a in d6-DMSO, 500 MHz 
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B-111 1H NMR Spectrum of glycosphingolipid 113a in d5-pyridine, 500 MHz 
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B-112 1H NMR Spectrum of glycosphingolipid 113b in d6-DMSO, 500 MHz 
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B-113 1H NMR Spectrum of glycosphingolipid 113c in d6-DMSO, 500 MHz 
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B-114 1H NMR Spectrum of glycosphingolipid 113d in d6-DMSO, 500 MHz. 
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B-115 1H NMR Spectrum of glycosphingolipid 114a-b in d6-DMSO, 500 MHz. 
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150 100 50 PPM 
B-116 13C NMR Spectrum of glycosphingolipid 114a-b in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-117 gCOSY data of glycosphingolipid 114a-b in d6-DMSO, 500 MHz 
240 
 
Appendix B (continued) 
 
 
B-118 gHMBC data of glycosphingolipid 114a-b in d6-DMSO, 500 MHz 
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Appendix B (continued) 
 
 
B-119 gHMQC data of glycosphingolipid 114a-b in d6-DMSO, 500 MHz 
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Appendix C: Mass Spectral Data 
 
C-1 LR ESIMS (positive) data for 103 
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Appendix C (continued) 
 
C-2 HR ESIMS (positive) data for 107 
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Appendix C (continued) 
 
C-3 HR ESIMS (positive) data for 108 and 109 
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Appendix C (continued) 
 
C-4 HR ESIMS (positive) data for 110 
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Appendix C (continued) 
 
C-5 HR ESIMS (positive) data for 111 
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Appendix C (continued) 
 
C-6 HR ESIMS (positive) data for 112 
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Appendix C (continued) 
 
C-7 LR APCI-MS (positive) data for glycoshingolipid 113 
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Appendix C (continued) 
 
C-8 LR APCI-MS (positive) data for glycoshingolipid 113a 
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Appendix C (continued) 
 
C-9 LR APCI-MS (positive) data for glycoshingolipid 113b 
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Appendix C (continued) 
 
C-10 LR APCI-MS (positive) data for glycoshingolipid 113c 
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Appendix C (continued) 
 
C-11 LR APCI-MS (positive) data for glycoshingolipid 113d 
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Appendix C (continued) 
 
C-12 LR APCI-MS (positive) data for glycoshingolipids 114a-b 
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Appendix D: Bioassay Data 
D-1 Palmerolide A UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.95461361  DF Adj r^2=0.93645905  FitStdErr=0.085229247  Fstat=77.121135
a=0.090975965 b=0.9548449 
c=0.011263561 d=0.91447148 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.97622158  DF Adj r^2=0.96671021  FitStdErr=0.065711532  Fstat=150.53475
a=0.080745796 b=0.78674703 
c=0.035593224 d=2.080209 
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0.002 µM (v-ATPase) 
0.024 µM (UACC-62) compared to NCI 0.018 µM
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D-2 Palmerolide B UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0 99927187  DF Adj r^2=0.99898061  FitStdErr=0.013250897  Fstat=5032 0399
a=0.0068052017 b=1.0029625 
c=0.23506557 d=1.2374706 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99999089  DF Adj r^2=0.99996357  FitStdErr=0.0027772691  Fstat=36603.506
a=0.070727065 b=0.93127039 
c=0.26880172 d=1.6539878 
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D-3 Palmerolide C UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.96957639  DF Adj r^2=0.96146343  FitStdErr=0.036818162  Fstat=169.96913
a=0.059800515 b=0.41034065 
c=0.12257149 d=3.7661815 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.9987207  DF Adj r^2=0.99837956  FitStdErr=0.016245663  Fstat=4163.6209
a=0.086230565 b=0 92315348 
c=0.089321713 d=1.7605982 
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0.025 µM (v-ATPase) 
0.002 µM (UACC-62)
D-4 Palmerolide D UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.98799544  DF Adj r^2=0.98399392  FitStdErr=0.036349087  Fstat=356.6406
a=0.059483839 b=1.5312387 
c=0.0010091719 d=1.4206199 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.98577193  DF Adj r^2=0.94308771  FitStdErr=0.087756255  Fstat=23.09453
a=0.032591955 b=1.3640241 
c=0.00285681 d=0.58449391 
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D-5 Palmerolide E UACC-62 data plot 
 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99410493  DF Adj r^2=0.99073631  FitStdErr=0.032194718  Fstat=449.6885
a=0.13716696 b=0.84116638 
c=5.5371635 d=4.5722235 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99903732  DF Adj r^2=0.99848721  FitStdErr=0.015597364  Fstat=2767.3643
a=0.040817254 b=0.95296052 
c=4.1467107 d=5.8459316 
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D-6 Palmerolide F UACC-62 data plot 
  
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99596443  DF Adj r^2=0.9943502  FitStdErr=0.028279405  Fstat=904.91999
a=0.14335109 b=0.83890449 
c=0.69987786 d=4.6438677 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99933685  DF Adj r^2=0.99904212  FitStdErr=0.012903565  Fstat=5023.216
a=0.064133334 b=0.93586667 
c=0.81461891 d=7.0785315 
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D-7 Palmerolide G UACC-62 data plot 
  
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99908376  DF Adj r^2=0.99867654  FitStdErr=0.014004236  Fstat=3634.7294
a=0.003431838 b=0.99678018 
c=1.4786218 d=2.6186998 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99985018  DF Adj r^2=0.99979025  FitStdErr=0.0058273255  Fstat=24469.833
a=0.010000012 b=0.98999999 
c=0.93405357 d=5.8896305 
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D-8 Palmerolide H UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99274514  DF Adj r^2=0.9898432  FitStdErr=0.040066471  Fstat=501.74198
a=0.10207459 b=0.89969451 
c=0.023309733 d=2.0054029 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99690293  DF Adj r^2=0.9956641  FitStdErr=0.026816115  Fstat=1180.2478
a=0.11086954 b=0.88912924 
c=0.014991273 d=5.0628148 
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D-9 Palmerolide A pBrBz C-7 monoester UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99706517  DF Adj r^2=0.99589124  FitStdErr=0.024832382  Fstat=1245.6958
a=0.089945228 b=0.87790476 
c=0.34690528 d=1.8393336 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.9956321  DF Adj r^2=0.99388493  FitStdErr=0.025497327  Fstat=835.79007
a=0.11634907 b=0.73110503 
c=0.73598201 d=5.1082043 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99657083  DF Adj r^2=0.99519917  FitStdErr=0.02180372  Fstat=1065.592
a=0.12240146 b=0.73659195 
c=0.71567909 d=3.0065856 
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D-10 Palmerolide A pBrBz C-10 monoester UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.9894007  DF Adj r^2=0.98516098  FitStdErr=0.040023251  Fstat=342.26822
a=0.12068255 b=0.74684554 
c=0.3185954 d=1.729595 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.98326172  DF Adj r^2=0.97656641  FitStdErr=0.049913722  Fstat=215.39209
a=0.12202144 b=0.75375364 
c=0.39619193 d=1.6592696 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99666403  DF Adj r^2=0.99532964  FitStdErr=0.026692665  Fstat=1095.4629
a=0.099949409 b=0.88954677 
c=0.21192074 d=1.699866 
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D-11 Palmerolide A carbamate hydrolysis product UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99605295  DF Adj r^2=0.99447413  FitStdErr=0.028713103  Fstat=925.29735
a=0.10741706 b=0.88007182 
c=0.58094259 d=2.5713388 
0.001 0.01 0.1 1 10
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
         
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.95737659  DF Adj r^2=0.94032723  FitStdErr=0.091480651  Fstat=82.358056
a=-0.27791647 b=1.4402454 
c=0.39690655 d=0.40115028 
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D-12 Palmerolide A NaOH conjugate addition/carbamate dehydration product UACC-62 data plot 
Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.99999938  DF Adj r^2=0.99999752  FitStdErr=0.00074214912  Fstat=537716.26
a=0.018000001 b=0.982 
c=0.87529052 d=6.7979591 
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Eqn 8013  LgstcDoseRsp(a,b,c,d)
r^2=0.9999993  DF Adj r^2=0.99999722  FitStdErr=0.00081109102  Fstat=479485.05
a=0.021000001 b=0 979 
c=0.82414906 d=6.971688 
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